
PART I.	FINANCIAL INFORMATION		1

	Item 1.	Condensed Consolidated Financial Statements	1

		Condensed Consolidated Balance Sheets as of ~~March 31,~~June 30, 2022 and December 31, 2021 (unaudited)	1

		Condensed Consolidated Statements of Operations for the Three and Six Months Ended ~~March 31,~~June 30, 2022 and 2021 (unaudited)	2

		Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended ~~March 31,~~June 30, 2022 and 2021 (unaudited)	3

		Condensed Consolidated Statements of Shareholders’ Equity for the Three and Six Months Ended ~~March 31,~~June 30, 2022 and 2021 (unaudited)	4

		Condensed Consolidated Statements of Cash Flows for the ~~Three~~Six Months Ended ~~March 31,~~June 30, 2022 and 2021 (unaudited)	56

		Notes to Condensed Consolidated Financial Statements (unaudited)	67

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2730

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	5661

	Item 4.	Controls and Procedures	5862

PART II.	OTHER INFORMATION		5862

	Item 1.	Legal Proceedings	5862

	Item 1A.	Risk Factors	5862

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	5862

	Item 3.	Defaults Upon Senior Securities	5862

	Item 4.	Mine Safety Disclosures	5963

	Item 5.	Other Information	5963

	Item 6.	Exhibits	5963

This Quarterly Report on Form 10-Q contains statements reflecting our views about our future performance that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective assets, our industry, our beliefs and our assumptions. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of the numerous risks outlined in Part I under Item 1A. under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

Although we believe the expectations reflected in the forward-looking statements are reasonable, any of those expectations could prove to be inaccurate, and as a result, the forward-looking statements based on those expectations also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Quarterly Report on Form 10-Q should not be regarded as a representation by us that our plans and business objectives will be achieved. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We are under no duty to update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform our prior statements to actual results or revised expectations.


		As of March 31,		As of December 31,			As of June 30,		As of December 31,
		2022		2021			2022		2021
Assets	Assets					Assets
Current assets	Current assets					Current assets
Cash and cash equivalents	Cash and cash equivalents	$	1,791,517	$	1,541,048	Cash and cash equivalents	$	2,108,037	$	1,541,048

Marketable securities	Marketable securities	484,221		581,872		Marketable securities	290,402		581,872
Financial royalty assets	Financial royalty assets	570,684		614,351		Financial royalty assets	639,244		614,351
Accrued royalty receivable	Accrued royalty receivable	51,190		53,286		Accrued royalty receivable	18,032		53,286

Available for sale debt securities	Available for sale debt securities	64,800		66,000		Available for sale debt securities	363,700		66,000

Other royalty income receivable	Other royalty income receivable	14,618		15,023		Other royalty income receivable	17,315		15,023
Other current assets	Other current assets	5,388		6,631		Other current assets	67,119		6,631
Total current assets	Total current assets	2,982,418		2,878,211		Total current assets	3,503,849		2,878,211

Financial royalty assets, net	Financial royalty assets, net	13,467,211		13,718,245		Financial royalty assets, net	13,423,629		13,718,245
Intangible royalty assets, net	Intangible royalty assets, net	—		5,670		Intangible royalty assets, net	—		5,670
Equity securities	Equity securities	267,638		269,800		Equity securities	304,447		269,800
Available for sale debt securities	Available for sale debt securities	239,600		204,400		Available for sale debt securities	63,000		204,400

Equity method investments	Equity method investments	418,151		435,394		Equity method investments	412,076		435,394
Other assets	Other assets	3,870		4,145		Other assets	33,412		4,145

Total assets	Total assets	$	17,378,888	$	17,515,865	Total assets	$	17,740,413	$	17,515,865

Liabilities and shareholders’ equity	Liabilities and shareholders’ equity					Liabilities and shareholders’ equity
Current liabilities	Current liabilities					Current liabilities
Distributions payable to non-controlling interests	Distributions payable to non-controlling interests	$	116,010	$	107,934	Distributions payable to non-controlling interests	$	115,990	$	107,934
Accounts payable and accrued expenses	Accounts payable and accrued expenses	6,662		5,620		Accounts payable and accrued expenses	12,175		5,620
Interest payable	Interest payable	13,199		57,696		Interest payable	54,162		57,696

Total current liabilities	Total current liabilities	135,871		171,250		Total current liabilities	182,327		171,250

Long-term debt	Long-term debt	7,101,138		7,096,070		Long-term debt	7,106,199		7,096,070

Other liabilities						Other liabilities	43,700		—

Total liabilities	Total liabilities	7,237,009		7,267,320		Total liabilities	7,332,226		7,267,320

Commitments and contingencies	Commitments and contingencies	0		0		Commitments and contingencies	0		0
Shareholders’ equity	Shareholders’ equity					Shareholders’ equity

Class A ordinary shares, $0.0001 par value; 435,316 and 432,963 issued and outstanding, respectively		43		43
Class B ordinary shares, $0.000001 par value; 171,862 and 174,213 issued and outstanding, respectively		—		—
Class A ordinary shares, $0.0001 par value; 437,139 and 432,963 issued and outstanding, respectively						Class A ordinary shares, $0.0001 par value; 437,139 and 432,963 issued and outstanding, respectively	44		43
Class B ordinary shares, $0.000001 par value; 170,081 and 174,213 issued and outstanding, respectively						Class B ordinary shares, $0.000001 par value; 170,081 and 174,213 issued and outstanding, respectively	—		—
Class R redeemable shares, £1 par value; 50 and 50 issued and outstanding, respectively	Class R redeemable shares, £1 par value; 50 and 50 issued and outstanding, respectively	63		63		Class R redeemable shares, £1 par value; 50 and 50 issued and outstanding, respectively	63		63
Deferred shares, $0.000001 par value; 363,521 and 361,170 issued and outstanding, respectively		—		—
Deferred shares, $0.000001 par value; 365,302 and 361,170 issued and outstanding, respectively						Deferred shares, $0.000001 par value; 365,302 and 361,170 issued and outstanding, respectively	—		—

Additional paid-in capital	Additional paid-in capital	3,543,204		3,507,533		Additional paid-in capital	3,570,585		3,507,533
Retained earnings	Retained earnings	2,224,677		2,255,179		Retained earnings	2,446,132		2,255,179
Non-controlling interests	Non-controlling interests	4,364,324		4,471,951		Non-controlling interests	4,380,938		4,471,951
Accumulated other comprehensive income	Accumulated other comprehensive income	12,304		16,491		Accumulated other comprehensive income	13,177		16,491
Treasury interests	Treasury interests	(2,736)		(2,715)		Treasury interests	(2,752)		(2,715)

Total shareholders’ equity	Total shareholders’ equity	10,141,879		10,248,545		Total shareholders’ equity	10,408,187		10,248,545

Total liabilities and shareholders’ equity	Total liabilities and shareholders’ equity	$	17,378,888	$	17,515,865	Total liabilities and shareholders’ equity	$	17,740,413	$	17,515,865


		For the Three Months Ended March 31,				For the Three Months Ended June 30,				For the Six Months Ended June 30,
		2022		2021				2022		2021		2022		2021
Total income and revenues
Income and other revenues:							Income and other revenues:
Income from financial royalty assets	Income from financial royalty assets	$	511,523	$	529,625		Income from financial royalty assets	$	515,350	$	503,414	$	1,026,873	$	1,033,039
Revenue from intangible royalty assets	Revenue from intangible royalty assets	33,586		36,061			Revenue from intangible royalty assets	2,537		40,127		36,123		76,188
Other royalty income	Other royalty income	16,940		7,341			Other royalty income	18,068		11,422		35,008		18,763
Total income and other revenues	Total income and other revenues	562,049		573,027			Total income and other revenues	535,955		554,963		1,098,004		1,127,990

Operating expenses	Operating expenses						Operating expenses

Provision for changes in expected cash flows from financial royalty assets	Provision for changes in expected cash flows from financial royalty assets	184,621		292,262			Provision for changes in expected cash flows from financial royalty assets	105,714		(243,762)		290,335		48,499
Research and development funding expense	Research and development funding expense	100,500		2,641			Research and development funding expense	606		3,122		101,106		5,763
Amortization of intangible assets	Amortization of intangible assets	5,670		5,671			Amortization of intangible assets	—		5,733		5,670		11,404
General and administrative expenses	General and administrative expenses	51,540		43,156			General and administrative expenses	51,843		44,921		103,383		88,077

Total operating expenses, net		342,331		343,730
Total operating expenses/(income), net							Total operating expenses/(income), net	158,163		(189,986)		500,494		153,743

Operating income	Operating income	219,718		229,297			Operating income	377,792		744,949		597,510		974,247

Other (income)/expense	Other (income)/expense						Other (income)/expense
Equity in (earnings)/losses of equity method investees		(397)		1,918
Equity in earnings of equity method investees							Equity in earnings of equity method investees	(737)		(17,701)		(1,134)		(15,783)
Interest expense	Interest expense	47,063		37,415			Interest expense	46,966		37,426		94,029		74,841

Losses on derivative financial instruments		—		2,555
Losses on equity securities		36,162		54,186
(Gains)/losses on derivative financial instruments							(Gains)/losses on derivative financial instruments	(71,805)		1,909		(71,805)		4,464
(Gains)/losses on equity securities							(Gains)/losses on equity securities	(8,024)		(55,495)		28,138		(1,309)

Unrealized losses/(gains) on available for sale debt securities		16,579		(9,115)
Unrealized gains on available for sale debt securities							Unrealized gains on available for sale debt securities	(70,321)		(14,015)		(53,742)		(23,130)
Interest income	Interest income	(9,529)		(16,598)			Interest income	(10,919)		(14,037)		(20,448)		(30,635)
Other non-operating expense/(income), net		1,757		(43)
Total other expenses, net		91,635		70,318
Other non-operating expense, net							Other non-operating expense, net	1,035		107		2,792		65
Total other (income)/expenses, net							Total other (income)/expenses, net	(113,805)		(61,806)		(22,170)		8,513
Consolidated net income before tax	Consolidated net income before tax	128,083		158,979			Consolidated net income before tax	491,597		806,755		619,680		965,734
Income tax expense	Income tax expense	—		—			Income tax expense	—		—		—		—
Consolidated net income	Consolidated net income	128,083		158,979			Consolidated net income	491,597		806,755		619,680		965,734

Net income attributable to non-controlling interests	Net income attributable to non-controlling interests	76,322		89,860			Net income attributable to non-controlling interests	187,093		365,979		263,415		455,839

Net income attributable to Royalty Pharma plc	Net income attributable to Royalty Pharma plc	$	51,761	$	69,119		Net income attributable to Royalty Pharma plc	$	304,504	$	440,776	$	356,265	$	509,895

Earnings per Class A ordinary share:	Earnings per Class A ordinary share:						Earnings per Class A ordinary share:
Basic	Basic	$	0.12	$	0.18		Basic	$	0.70	$	1.08	$	0.82	$	1.28
Diluted	Diluted	$	0.12	$	0.18		Diluted	$	0.70	$	1.08	$	0.82	$	1.25
Weighted average Class A ordinary shares outstanding:	Weighted average Class A ordinary shares outstanding:						Weighted average Class A ordinary shares outstanding:
Basic	Basic	433,956		389,760			Basic	436,318		409,344		435,144		399,606
Diluted	Diluted	607,201		607,148			Diluted	607,214		607,163		607,207		607,151


		For the Three Months Ended March 31,					For the Three Months Ended June 30,				For the Six Months Ended June 30,
		2022		2021			2022		2021		2022		2021
Consolidated net income	Consolidated net income	$	128,083	$	158,979	Consolidated net income	$	491,597	$	806,755	$	619,680	$	965,734
Changes in other comprehensive income/(loss):	Changes in other comprehensive income/(loss):	0		0		Changes in other comprehensive income/(loss):

Unrealized gains on available for sale debt securities	Unrealized gains on available for sale debt securities	1,625		5,125		Unrealized gains on available for sale debt securities	9,325		6,025		10,950		11,150
Reclassification of unrealized gains on available for sale debt securities	Reclassification of unrealized gains on available for sale debt securities	(8,954)		(15,491)		Reclassification of unrealized gains on available for sale debt securities	(7,988)		(13,299)		(16,942)		(28,790)
Total other comprehensive losses		$	(7,329)	$	(10,366)
Other comprehensive income/(loss)						Other comprehensive income/(loss)	$	1,337	$	(7,274)	$	(5,992)	$	(17,640)
Comprehensive income	Comprehensive income	$	120,754	$	148,613	Comprehensive income	$	492,934	$	799,481	$	613,688	$	948,094
Comprehensive income attributable to non-controlling interests	Comprehensive income attributable to non-controlling interests	73,310		84,979		Comprehensive income attributable to non-controlling interests	187,638		362,748		260,948		447,727
Comprehensive income attributable to Royalty Pharma plc	Comprehensive income attributable to Royalty Pharma plc	$	47,444	$	63,634	Comprehensive income attributable to Royalty Pharma plc	$	305,296	$	436,733	$	352,740	$	500,367


		Class A Ordinary Shares			Class B Ordinary Shares			Class R Redeemable Shares			Deferred Shares			Additional Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Income		Non-Controlling Interests		Treasury Interests		Total Equity			Class A Ordinary Shares			Class B Ordinary Shares			Class R Redeemable Shares			Deferred Shares			Additional Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Income		Non-Controlling Interests		Treasury Interests		Total Equity
		Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount															Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount
Balance at December 31, 2021		432,963	$	43	174,213	$	—	50	$	63	361,170	$	—	$	3,507,533	$	2,255,179	$	16,491	$	4,471,951	$	(2,715)	$	10,248,545
Balance at March 31, 2022																										Balance at March 31, 2022	435,316	$	43	171,862	$	—	50	$	63	363,521	$	—	$	3,543,204	$	2,224,677	$	12,304	$	4,364,324	$	(2,736)	$	10,141,879
Contributions	Contributions	—	—		—	—		—	—		—	—		—		—		—		3,323		—		3,323		Contributions	—	—		—	—		—	—		—	—		—		—		—		2,881		—		2,881
Distributions	Distributions	—	—		—	—		—	—		—	—		—		—		—		(148,976)		—		(148,976)		Distributions	—	—		—	—		—	—		—	—		—		—		—		(146,967)		—		(146,967)
Dividends ($0.19 per Class A ordinary share)	Dividends ($0.19 per Class A ordinary share)	—	—		—	—		—	—		—	—		—		(82,263)		—		—		—		(82,263)		Dividends ($0.19 per Class A ordinary share)	—	—		—	—		—	—		—	—��		—		(83,049)		—		—		—		(83,049)
Other exchanges	Other exchanges	2,351	—		(2,351)	—		—	—		2,351	—		35,175		—		130		(35,284)		(21)		—		Other exchanges	1,781	1		(1,781)	—		—	—		1,781	—		26,872		—		81		(26,938)		(16)		—
Share-based compensation and related issuances of Class A ordinary shares	Share-based compensation and related issuances of Class A ordinary shares	2	—		—	—		—	—		—	—		496		—		—		—		—		496		Share-based compensation and related issuances of Class A ordinary shares	42	—		—	—		—	—		—	—		509		—		—		—		—		509
Net income	Net income	—	—		—	—		—	—		—	—		—		51,761		—		76,322		—		128,083		Net income	—	—		—	—		—	—		—	—		—		304,504		—		187,093		—		491,597
Other comprehensive income/(loss):	Other comprehensive income/(loss):																									Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities	Unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—		—		957		668		—		1,625		Unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—		—		5,523		3,802		—		9,325
Reclassification of unrealized gains on available for sale debt securities	Reclassification of unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—		—		(5,274)		(3,680)		—		(8,954)		Reclassification of unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—		—		(4,731)		(3,257)		—		(7,988)

Balance at March 31, 2022		435,316	$	43	171,862	$	—	50	$	63	363,521	$	—	$	3,543,204	$	2,224,677	$	12,304	$	4,364,324	$	(2,736)	$	10,141,879
Balance at June 30, 2022																										Balance at June 30, 2022	437,139	$	44	170,081	$	—	50	$	63	365,302	$	—	$	3,570,585	$	2,446,132	$	13,177	$	4,380,938	$	(2,752)	$	10,408,187


		Class A Ordinary Shares			Class B Ordinary Shares			Class R Redeemable Shares			Deferred Shares			Additional Paid-In Capital			Retained Earnings		Accumulated Other Comprehensive Income		Non-Controlling Interests		Treasury Interests		Total Equity			Class A Ordinary Shares			Class B Ordinary Shares			Class R Redeemable Shares			Deferred Shares			Additional Paid-In Capital			Retained Earnings		Accumulated Other Comprehensive Income		Non-Controlling Interests		Treasury Interests		Total Equity
		Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount				Retained Earnings											Shares	Amount	Shares		Amount	Shares		Amount	Shares		Amount	Additional Paid-In Capital				Accumulated Other Comprehensive Income
Balance at December 31, 2020		388,135	$	39	218,976	$	—	50	$	63	316,407	$	—	$	2,865,964		$	1,920,635	$	34,395	$	5,077,036	$	(2,317)	$	9,895,815
Balance at March 31, 2021																											Balance at March 31, 2021	392,857	$	39	214,255	$	—	50	$	63	321,128			$	—		$	2,931,249			$	1,923,771	$	29,452	$	4,954,818	$	(2,359)	$	9,837,033
Contributions	Contributions	—	—		—	—		—	—		—	—		—			—		—		3,253		—		3,253		Contributions	—	—		—	—		—	—		—	—		—			—		—		11,519		—		11,519
Distributions	Distributions	—	—		—	—		—	—		—	—		—			—		—		(145,378)		—		(145,378)		Distributions	—	—		—	—		—	—		—	—		—			—		—		(170,808)		—		(170,808)
Dividends ($0.17 per Class A ordinary share)	Dividends ($0.17 per Class A ordinary share)	—	—		—	—		—	—		—	—		—			(65,983)		—		—		—		(65,983)		Dividends ($0.17 per Class A ordinary share)	—	—		—	—		—	—		—	—		—			(72,581)		—		—		—		(72,581)
Other exchanges	Other exchanges	4,721	—		(4,721)	—		—	—		4,721	—		64,572			—		542		(65,072)		(42)		—		Other exchanges	34,089	3		(34,089)	—		—	—		34,089	—		483,628			—		3,263		(486,591)		(303)		—
Share-based compensation and related issuances of Class A ordinary shares	Share-based compensation and related issuances of Class A ordinary shares	1	—		—	—		—	—		—	—		713			—		—		—		—		713		Share-based compensation and related issuances of Class A ordinary shares	60	—		—	—		—	—		—	—		721			—		—		—		—		721
Net income	Net income	—	—		—	—		—	—		—	—		—			69,119		—		89,860		—		158,979		Net income	—	—		—	—		—	—		—	—		—			440,776		—		365,979		—		806,755
Other comprehensive income/(loss):	Other comprehensive income/(loss):																										Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities	Unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—			—		2,712		2,413		—		5,125		Unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—			—		3,348		2,677		—		6,025
Reclassification of unrealized gains on available for sale debt securities	Reclassification of unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—			—		(8,197)		(7,294)		—		(15,491)		Reclassification of unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—			—		(7,391)		(5,908)		—		(13,299)

Balance at March 31, 2021		392,857	$	39	214,255	$	—	50	$	63	321,128	$	—	$	2,931,249		$	1,923,771	$	29,452	$	4,954,818	$	(2,359)	$	9,837,033
Balance at June 30, 2021																											Balance at June 30, 2021	427,006	$	42	180,166	$	—	50	$	63	355,217	$	—	$	3,415,598		$	2,291,966	$	28,672	$	4,671,686	$	(2,662)	$	10,405,365


	Class A Ordinary Shares			Class B Ordinary Shares			Class R Redeemable Shares			Deferred Shares			Additional Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Income		Non-Controlling Interests		Treasury Interests		Total Equity
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount
Balance at December 31, 2021	432,963	$	43	174,213	$	—	50	$	63	361,170	$	—	$	3,507,533	$	2,255,179	$	16,491	$	4,471,951	$	(2,715)	$	10,248,545
Contributions	—	—		—	—		—	—		—	—		—		—		—		6,203		—		6,203
Distributions	—	—		—	—		—	—		—	—		—		—		—		(295,942)		—		(295,942)
Dividends ($0.38 per Class A ordinary share)	—	—		—	—		—	—		—	—		—		(165,312)		—		—		—		(165,312)
Other exchanges	4,132	1		(4,132)	—		—	—		4,132	—		62,047		—		211		(62,222)		(37)		—
Share based compensation and related issuances of Class A ordinary shares	44	—		—	—		—	—		—	—		1,005		—		—		—		—		1,005
Net income	—	—		—	—		—	—		—	—		—		356,265		—		263,415		—		619,680
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—		—		6,480		4,470		—		10,950
Reclassification of unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—		—		(10,005)		(6,937)		—		(16,942)

Balance at June 30, 2022	437,139	$	44	170,081	$	—	50	$	63	365,302	$	—	$	3,570,585	$	2,446,132	$	13,177	$	4,380,938	$	(2,752)	$	10,408,187


	Class A Ordinary Shares			Class B Ordinary Shares			Class R Redeemable Shares			Deferred Shares			Additional Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Income		Non-Controlling Interests		Treasury Interests		Total Equity
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount
Balance at December 31, 2020	388,135	$	39	218,976	$	—	50	$	63	316,407	$	—	$	2,865,964	$	1,920,635	$	34,395	$	5,077,036	$	(2,317)	$	9,895,815
Contributions	—	—		—	—		—	—		—	—		—		—		—		14,772		—		14,772


Distributions	—	—		—	—		—	—		—	—		—		—		—		(316,186)		—		(316,186)





Dividends ($0.34 per Class A ordinary share)	—	—		—	—		—	—		—	—		—		(138,564)		—		—		—		(138,564)
Other exchanges	38,810	3		(38,810)	—		—	—		38,810	—		548,200		—		3,805		(551,663)		(345)		—
Share-based compensation and related issuances of Class A ordinary shares	61	—		—	—		—	—		—	—		1,434		—		—		—		—		1,434

Net income	—	—		—	—		—	—		—	—		—		509,895		—		455,839		—		965,734
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—		—		6,060		5,090		—		11,150
Reclassification of unrealized gains on available for sale debt securities	—	—		—	—		—	—		—	—		—		—		(15,588)		(13,202)		—		(28,790)

Balance at June 30, 2021	427,006	$	42	180,166	$	—	50	$	63	355,217	$	—	$	3,415,598	$	2,291,966	$	28,672	$	4,671,686	$	(2,662)	$	10,405,365


		For the Three Months Ended March 31,					For the Six Months Ended June 30,
		2022		2021			2022		2021
Cash flows from operating activities:	Cash flows from operating activities:					Cash flows from operating activities:
Cash collections from financial royalty assets	Cash collections from financial royalty assets	$	621,689	$	573,946	Cash collections from financial royalty assets	$	1,181,354	$	1,094,094
Cash collections from intangible royalty assets	Cash collections from intangible royalty assets	35,682		35,761		Cash collections from intangible royalty assets	71,377		75,200
Other royalty cash collections	Other royalty cash collections	17,345		6,821		Other royalty cash collections	32,716		14,088
Distributions from equity method investees	Distributions from equity method investees	20,690		17,325		Distributions from equity method investees	27,502		22,003
Interest received	Interest received	482		1,548		Interest received	3,262		2,332

Derivative collateral received						Derivative collateral received	—		11,470
Derivative collateral posted						Derivative collateral posted	—		(9,340)

Development-stage funding payments - ongoing	Development-stage funding payments - ongoing	(500)		(2,641)		Development-stage funding payments - ongoing	(1,106)		(5,763)
Development-stage funding payments - upfront and milestones		(100,000)		—
Development-stage funding payments - upfront and milestone						Development-stage funding payments - upfront and milestone	(100,000)		—
Payments for operating and professional costs	Payments for operating and professional costs	(48,902)		(42,160)		Payments for operating and professional costs	(93,003)		(81,764)

Interest paid	Interest paid	(86,216)		(64,500)		Interest paid	(86,880)		(64,500)
Net cash provided by operating activities	Net cash provided by operating activities	460,270		526,100		Net cash provided by operating activities	1,035,222		1,057,820

Cash flows from investing activities:	Cash flows from investing activities:					Cash flows from investing activities:

Distributions from equity method investees						Distributions from equity method investees	—		523
Investments in equity method investees	Investments in equity method investees	(3,050)		(8,714)		Investments in equity method investees	(3,050)		(17,427)
Purchases of equity securities	Purchases of equity securities	(34,000)		—		Purchases of equity securities	(62,785)		—

Proceeds from equity securities						Proceeds from equity securities	—		109,367
Purchases of available for sale debt securities	Purchases of available for sale debt securities	(64,579)		(17,585)		Purchases of available for sale debt securities	(79,158)		(35,170)
Proceeds from available for sale debt securities	Proceeds from available for sale debt securities	15,625		15,625		Proceeds from available for sale debt securities	31,250		31,250
Purchases of marketable securities	Purchases of marketable securities	(177,354)		(505,339)		Purchases of marketable securities	(234,869)		(728,025)
Proceeds from sales and maturities of marketable securities	Proceeds from sales and maturities of marketable securities	274,608		419,783		Proceeds from sales and maturities of marketable securities	525,907		868,689

Acquisitions of financial royalty assets	Acquisitions of financial royalty assets	(85)		(503,070)		Acquisitions of financial royalty assets	(175,093)		(683,741)

Net cash provided by/(used in) investing activities		11,165		(599,300)
Acquisitions of other financial assets						Acquisitions of other financial assets	(21,215)		—
Milestone payments						Milestone payments	—		(18,600)
Net cash used in investing activities						Net cash used in investing activities	(19,013)		(473,134)

Cash flows from financing activities:	Cash flows from financing activities:					Cash flows from financing activities:

Distributions to non-controlling interests	Distributions to non-controlling interests	(106,385)		(125,721)		Distributions to non-controlling interests	(215,543)		(238,197)
Distributions to non-controlling interests- other	Distributions to non-controlling interests- other	(34,515)		(37,183)		Distributions to non-controlling interests- other	(72,343)		(86,978)
Dividends to shareholders	Dividends to shareholders	(82,263)		(65,983)		Dividends to shareholders	(165,312)		(138,564)

Contributions from non-controlling interests- R&D	Contributions from non-controlling interests- R&D	624		1,997		Contributions from non-controlling interests- R&D	731		4,080
Contributions from non-controlling interests- other	Contributions from non-controlling interests- other	1,573		220		Contributions from non-controlling interests- other	3,247		8,574

Net cash used in financing activities	Net cash used in financing activities	(220,966)		(226,670)		Net cash used in financing activities	(449,220)		(451,085)
Net change in cash and cash equivalents	Net change in cash and cash equivalents	250,469		(299,870)		Net change in cash and cash equivalents	566,989		133,601
Cash and cash equivalents, beginning of period	Cash and cash equivalents, beginning of period	1,541,048		1,008,680		Cash and cash equivalents, beginning of period	1,541,048		1,008,680
Cash and cash equivalents, end of period	Cash and cash equivalents, end of period	$	1,791,517	$	708,810	Cash and cash equivalents, end of period	$	2,108,037	$	1,142,281

Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (“IPO”) of our Class A ordinary ~~shares that was completed in June 2020.~~shares. “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.

~~Following our IPO, we~~We control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings’ Class A ordinary shares ~~(the “RP Holdings Class A Interests”)~~ and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). The Continuing Investors Partnerships (defined below) have a non-controlling interest in RP Holdings through their ownership of RP Holdings Class B Interests. We conduct our business through RP Holdings and its subsidiaries.

RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”)~~, for accounting and financial reporting purposes.~~. RP Holdings is directly or indirectly owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”), and Royalty Pharma plc. ~~Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990.~~ Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

~~In connection with our IPO, we~~We consummated an exchange offer on February 11, ~~2020.~~2020 to facilitate the IPO. Through the exchange offer, investors ~~representing~~which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under senior secured credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer ~~Transactions”.~~Transactions.”

As a result of the Exchange Offer Transactions, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”)~~, an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we~~. We are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust.

In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K.

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.

~~As the United States and global economies have begun to recover from the COVID-19 pandemic with many health and safety restrictions lifted and increased vaccine distribution, we~~We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not ~~resulted in~~had a material ~~effect to~~impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.

The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record Net income attributable to non-controlling interests inon our ~~unaudited~~ condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI, (2) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain conditions are met.

Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of ~~March 31,~~June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.

The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, ~~Gilead,~~ Johnson & Johnson, Merck & Co., Pfizer, Astellas, Novartis, ~~Biogen~~ and ~~Vertex.~~Gilead. As of ~~March 31,~~June 30, 2022 and December 31, 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% of our current portion of ~~Financial~~financial royalty assets ~~net~~, and represented the largest individual marketer and payor of our royalties.

On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (“Cytokinetics”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. As part of the funding agreement, we agreed to provide ~~up to $300 million of~~ capital (“Cytokinetics Commercial Launch Funding”) of up to $300 million, which is ~~available in~~comprised of 5 tranches, including an initial tranche of $50 million that was funded upon closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw ~~$25~~$50 million if a certain contingency is met and has the option to draw the remaining ~~$225~~$200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”). As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022. Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn.

~~The Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recognized at fair value within~~ ~~Available for sale debt securities~~ ~~in the condensed consolidated balance sheets.~~ We ~~have~~ elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within Available for sale debt securities on the condensed consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within Other liabilities as of June 30, 2022 and within Available for sale debt securities as of December 31, 2021 on the condensed consolidated balance sheets. The unrealized change in fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within Unrealized ~~losses/(gains)~~gains on available for sale debt securities onin the condensed consolidated statements of operations.

On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support ~~MorphoSys’~~its acquisition of Constellation Pharmaceuticals, Inc. ~~(“Constellation”)~~ that closed on July 15, 2021. As part of the funding agreement, which was amended in the three months ended June 30, 2022 to extend the initial funding date, we agreed to provide MorphoSys up to $350 million of capital (the “Development Funding Bonds”)~~, which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation.~~ to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $150 million. Our commitment to fund at least $150 million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding is drawn. As of ~~March 31,~~June 30, 2022, MorphoSys ~~has~~had not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $300 million under the Development Funding Bonds to be funded in September 2022.

We ~~have~~ elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within Other liabilities as of June 30, 2022 and within Available for sale debt securities inas of December 31, 2021 on our condensed consolidated balance sheets. The unrealized change in fair value of the Development Funding Bond Forward is recorded within Unrealized ~~losses/(gains)~~gains on available for sale debt securities onin the condensed consolidated statements of operations.

On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) at a price of $50,100 per preferred share for a total of $125 million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (“FDA”) in February 2020 resulted in a payment due to us of 2 times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to 2 times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price.

The Series A Biohaven Preferred Shares are classified as Available for sale debt securities on our condensed consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of comprehensive income. In the three and six months ended June 30, 2022, $8.0 million and $16.9 million, respectively, of the unrealized gains were reclassified from other comprehensive income to Interest income in the condensed consolidated statements of operations. In the three and six months ended June 30, 2021, $13.3 million and $28.8 million, respectively, of the unrealized gains were reclassified from other comprehensive income to Interest income in the condensed consolidated statements of operations.

On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven ~~Pharmaceutical Holding Company Ltd. (“Biohaven”)~~ where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $200 million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between the three months ended March 31, 2025 and the three months ended December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the original issue price of the Series B Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares.

~~In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares.~~ As of ~~March 31,~~June 30, 2022, we have acquired ~~1,697~~1,988 shares of Series B Biohaven Preferred Shares. We ~~have~~ elected the fair value option to account for the Series B ~~Forwards~~Biohaven Preferred Shares and the Series B ~~Biohaven Preferred Shares,~~Forwards, which are recorded in aggregate ~~on the condensed consolidated balance sheets~~ as Available for sale debt securities.on the condensed consolidated balance sheets. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within Unrealized ~~losses/(gains) on available for sale debt securities~~ ~~on the condensed consolidated statements of operations.~~

On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven at a price of $50,100 per preferred share, for a total of $125 million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (“FDA”) in February 2020 resulted in a payment due to us of 2 times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to 2 times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price.

~~The Series A Biohaven Preferred Shares are classified as~~ ~~Available for sale debt securities~~ ~~in our condensed consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within~~ ~~Unrealized~~ gains on available for sale debt securities onin the condensed consolidated statements of ~~comprehensive income. In the three months ended March 31, 2022 and 2021, $9.0 million and $15.5 million of the unrealized gains were reclassified from other comprehensive income to~~ ~~Interest income~~ ~~on the condensed consolidated statements of operations, respectively.~~operations.


		Cost		Unrealized Gains/(Losses)		Fair Value		Current Assets		Non-Current Assets		Total			Cost		Unrealized Gains		Fair Value		Current Assets		Non-Current Assets		Current Liabilities		Non-Current Liabilities (3)		Total
As of March 31, 2022
As of June 30, 2022														As of June 30, 2022
Debt securities (1)	Debt securities (1)	$	271,817	$	42,183	$	314,000	$	64,800	$	249,200	$	314,000	Debt securities (1)	$	278,759	$	84,241	$	363,000	$	300,000	$	63,000	$	—	$	—	$	363,000
Forwards (2)	Forwards (2)	—		(1,200)		(1,200)		—		(1,200)		(1,200)		Forwards (2)	—		28,100		28,100		63,700		—		—		(35,600)		28,100
Funding commitments (2)	Funding commitments (2)	(9,400)		1,000		(8,400)		—		(8,400)		(8,400)		Funding commitments (2)	(9,400)		1,300		(8,100)		—		—		—		(8,100)		(8,100)
Total available for sale debt securities	Total available for sale debt securities	$	262,417	$	41,983	$	304,400	$	64,800	$	239,600	$	304,400	Total available for sale debt securities	$	269,359	$	113,641	$	383,000	$	363,700	$	63,000	$	—	$	(43,700)	$	383,000

As of December 31, 2021	As of December 31, 2021													As of December 31, 2021
Debt securities (1)	Debt securities (1)	$	204,509	$	49,191	$	253,700	$	66,000	$	187,700	$	253,700	Debt securities (1)	$	204,509	$	49,191	$	253,700	$	66,000	$	187,700	$	—	$	—	$	253,700
Forwards (2)	Forwards (2)	—		16,700		16,700		—		16,700		16,700		Forwards (2)	—		16,700		16,700		—		16,700		—		—		16,700
Total available for sale debt securities	Total available for sale debt securities	$	204,509	$	65,891	$	270,400	$	66,000	$	204,400	$	270,400	Total available for sale debt securities	$	204,509	$	65,891	$	270,400	$	66,000	$	204,400	$	—	$	—	$	270,400

On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (“Cytokinetics”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. As part of the funding agreement, we agreed to provide capital (“Cytokinetics Commercial Launch Funding”) of up to $300 million, which is comprised of 5 tranches, including an initial tranche of $50 million that was funded upon closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”). As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022. Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn.

We ~~determine~~elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within Available for sale debt securities on the condensed consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within Other liabilities as of June 30, 2022 and within Available for sale debt securities as of December 31, 2021 on the condensed consolidated balance sheets. The unrealized change in fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations.

On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support its acquisition of Constellation Pharmaceuticals, Inc. that closed on July 15, 2021. As part of the funding agreement, which was amended in the three months ended June 30, 2022 to extend the initial funding date, we agreed to provide MorphoSys up to $350 million of capital (the “Development Funding Bonds”) to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $150 million. Our commitment to fund at least $150 million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding is drawn. As of June 30, 2022, MorphoSys had not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $300 million under the Development Funding Bonds to be funded in September 2022.

We elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within Other liabilities as of June 30, 2022 and within Available for sale debt securities as of December 31, 2021 on our condensed consolidated balance sheets. The unrealized change in fair value of the Development Funding Bond Forward is recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations.

~~Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives,~~Unrealized gains on available for sale debt securities in the condensed consolidated statements of comprehensive income. In the three and ~~long-term debt. Cash~~six months ended June 30, 2022, $8.0 million and ~~cash equivalents, marketable~~$16.9 million, respectively, of the unrealized gains were reclassified from other comprehensive income to Interest income in the condensed consolidated statements of operations. In the three and six months ended June 30, 2021, $13.3 million and $28.8 million, respectively, of the unrealized gains were reclassified from other comprehensive income to Interest income in the condensed consolidated statements of operations.

On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”) for a total of $200 million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between the three months ended March 31, 2025 and the three months ended December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the original issue price of the Series B Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares.

As of June 30, 2022, we have acquired 1,988 shares of Series B Biohaven Preferred Shares. We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which are recorded in aggregate as Available for sale debt securities ~~equity securities, derivatives~~on the condensed consolidated balance sheets. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within Unrealized gains on available for sale debt securities ~~are reported at their respective fair values~~ in ~~our~~the condensed consolidated ~~balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level~~statements of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our condensed consolidated balance sheets at amounts that approximate current fair values.

As of March 31, 2022 As of December 31, 2021
Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total
Assets:
Cash equivalents
Money market funds $ 421,329 $ — $ — $ 421,329 $ 598,253 $ — $ — $ 598,253
Commercial paper — 56,540 — 56,540 — 13,997 — 13,997
Certificates of deposit — — — — — 40,954 — 40,954
U.S. government securities — 27,598 — 27,598 — — — —
Marketable securities
Commercial paper — 224,460 — 224,460 — 207,457 — 207,457
Certificates of deposit — 235,699 — 235,699 — 374,415 — 374,415
U.S. government securities — 24,062 — 24,062 — — — —
Available for sale debt securities
Debt securities (1) — — 64,800 64,800 — — 66,000 66,000
Total current assets $ 421,329 $ 568,359 $ 64,800 $ 1,054,488 $ 598,253 $ 636,823 $ 66,000 $ 1,301,076
Equity securities 205,100 — 62,538 267,638 226,787 — 43,013 269,800
Available for sale debt securities
Debt securities (1) — — 249,200 249,200 — — 187,700 187,700
Forwards (2) — — (1,200) (1,200) — — 16,700 16,700
Funding commitments (3) — — (8,400) (8,400) — — — —
Total non-current assets $ 205,100 $ — $ 302,138 $ 507,238 $ 226,787 $ — $ 247,413 $ 474,200


	Cost		Unrealized Gains		Fair Value		Current Assets		Non-Current Assets		Current Liabilities		Non-Current Liabilities (3)		Total
As of June 30, 2022
Debt securities (1)	$	278,759	$	84,241	$	363,000	$	300,000	$	63,000	$	—	$	—	$	363,000
Forwards (2)	—		28,100		28,100		63,700		—		—		(35,600)		28,100
Funding commitments (2)	(9,400)		1,300		(8,100)		—		—		—		(8,100)		(8,100)
Total available for sale debt securities	$	269,359	$	113,641	$	383,000	$	363,700	$	63,000	$	—	$	(43,700)	$	383,000

As of December 31, 2021
Debt securities (1)	$	204,509	$	49,191	$	253,700	$	66,000	$	187,700	$	—	$	—	$	253,700
Forwards (2)	—		16,700		16,700		—		16,700		—		—		16,700
Total available for sale debt securities	$	204,509	$	65,891	$	270,400	$	66,000	$	204,400	$	—	$	—	$	270,400

Three Months Ended March 31, 2022 Three Months Ended March 31, 2021
Equity Securities Debt Securities Forwards Funding Commitments Equity Securities Debt Securities Forwards Funding Commitments
Balance at the beginning of the period $ 43,013 $ 253,700 $ 16,700 $ — $ — $ 214,400 $ 18,600 $ —
Purchases — 64,579 — — — 17,585 — —
Gains/(losses) on initial recognition (1) — 9,400 — (9,400) — — — —
Gains on equity securities 19,525 — — — — — — —
Unrealized gains included in other comprehensive losses (2) — 1,625 — — 5,125 — —
Unrealized (losses)/gains included in earnings (3) — (1,600) (15,979) 1,000 — — 9,115 —
Settlement of forwards (4) — 1,921 (1,921) — — 5,315 (5,315) —
Redemption of debt securities — (15,625) — — — (15,625) — —
Balance at the end of the period $ 62,538 $ 314,000 $ (1,200) $ (8,400) $ — $ 226,800 $ 22,400 $ —

~~(3)Recorded within~~ ~~Unrealized losses/(gains) on available for sale debt securities~~ in the condensed consolidated statements of operations for unrealized losses/(gains) related to Series B Biohaven Preferred Shares and Series B Forwards for the three months ended March 31, 2022 and 2021. For the three months ended March 31, 2022, amounts also reflect unrealized losses related to the Development Funding Bond Forward and unrealized gains related tocost associated with the funded Cytokinetics Commercial Launch Funding ~~and the Cytokinetics Funding Commitments.~~

On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (“Cytokinetics”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. As part of the funding agreement, we agreed to provide capital (“Cytokinetics Commercial Launch Funding”) of up to $300 million, which is comprised of 5 tranches, including an initial tranche of $50 million that was funded upon closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”). As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022. Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn.

We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within Available for sale debt securities on the condensed consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within Other liabilities as of June 30, 2022 and within Available for sale debt securities as of December 31, 2021 on the condensed consolidated balance sheets. The unrealized change in fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations.


	Cost		Unrealized Gains		Fair Value		Current Assets		Non-Current Assets		Current Liabilities		Non-Current Liabilities (3)		Total
As of June 30, 2022
Debt securities (1)	$	278,759	$	84,241	$	363,000	$	300,000	$	63,000	$	—	$	—	$	363,000
Forwards (2)	—		28,100		28,100		63,700		—		—		(35,600)		28,100
Funding commitments (2)	(9,400)		1,300		(8,100)		—		—		—		(8,100)		(8,100)
Total available for sale debt securities	$	269,359	$	113,641	$	383,000	$	363,700	$	63,000	$	—	$	(43,700)	$	383,000

As of December 31, 2021
Debt securities (1)	$	204,509	$	49,191	$	253,700	$	66,000	$	187,700	$	—	$	—	$	253,700
Forwards (2)	—		16,700		16,700		—		16,700		—		—		16,700
Total available for sale debt securities	$	204,509	$	65,891	$	270,400	$	66,000	$	204,400	$	—	$	—	$	270,400

Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.


	As of June 30, 2022								As of December 31, 2021
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:

Cash equivalents
Money market funds	$	307,797	$	—	$	—	$	307,797	$	598,253	$	—	$	—	$	598,253
Commercial paper	—		181,681		—		181,681		—		13,997		—		13,997
Certificates of deposit	—		36,001		—		36,001		—		40,954		—		40,954

Marketable securities

Commercial paper	—		87,622		—		87,622		—		207,457		—		207,457
Certificates of deposit	—		178,766		—		178,766		—		374,415		—		374,415
U.S. government securities	—		24,014		—		24,014		—		—		—		—
Available for sale debt securities
Debt securities (1)	—		—		300,000		300,000		—		—		66,000		66,000
Forwards (2)	—		—		63,700		63,700		—		—		—		—
Derivative instrument (3)	—		—		63,200		63,200		—		—		—		—

Total current assets	$	307,797	$	508,084	$	426,900	$	1,242,781	$	598,253	$	636,823	$	66,000	$	1,301,076

Equity securities	275,662		—		28,785		304,447		226,787		—		43,013		269,800
Available for sale debt securities
Debt securities (1)	—		—		63,000		63,000		—		—		187,700		187,700
Forwards (2)	—		—		—		—		—		—		16,700		16,700


Derivative instrument (3)	—		—		8,600		8,600		—		—		—		—
Royalty at fair value (4)	—		—		21,215		21,215		—		—		—		—
Total non-current assets	$	275,662	$	—	$	121,600	$	397,262	$	226,787	$	—	$	247,413	$	474,200

Liabilities:




Available for sale debt securities
Forwards (2)	—		—		(35,600)		(35,600)		—		—		—		—
Funding commitments (5)	—		—		(8,100)		(8,100)		—		—		—		—
Total non-current liabilities	$	—	$	—	$	(43,700)	$	(43,700)	$	—	$	—	$	—	$	—

(2)Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within Other liabilities on the condensed consolidated balance sheet.


	For the Three Months Ended June 30, 2022												For the Three Months Ended June 30, 2021
	Equity Securities		Debt Securities		Forwards		Funding Commitments		Derivative Instrument		Royalty at Fair Value		Debt Securities		Forwards
Balance at the beginning of the period	$	62,538	$	314,000	$	(1,200)	$	(8,400)	$	—	$	—	$	226,800	$	22,400
Purchases	28,785		14,579		—		—		—		21,215		17,585		—

Losses on equity securities	(21,846)		—		—		—		—		—		—		—
Gains on derivative financial instrument	—		—		—		—		71,800		—		—		—
Unrealized gains included in other comprehensive losses (1)	—		9,325		—		—		—		—		6,025		—
Unrealized gains included in earnings (2)	—		31,800		38,221		300		—		—		500		13,515

Settlement of forwards (3)	—		8,921		(8,921)		—		—		—		5,115		(5,115)
Transfer to Level 1 (4)	(40,692)		—		—		—		—		—		—		—
Redemption of debt securities	—		(15,625)		—		—		—		—		(15,625)		—
Balance at the end of the period	$	28,785	$	363,000	$	28,100	$	(8,100)	$	71,800	$	21,215	$	240,400	$	30,800

(2)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.


	For the Six Months Ended June 30, 2022												For the Six Months Ended June 30, 2021
	Equity Securities		Debt Securities		Forwards		Funding Commitments		Derivative Instrument		Royalty at Fair Value		Debt Securities		Forwards
Balance at the beginning of the period	$	43,013	$	253,700	$	16,700	$	—	$	—	$	—	$	214,400	$	18,600
Purchases	28,785		79,158		—		—		—		21,215		35,170		—
Gains/(losses) on initial recognition (1)	—		9,400		—		(9,400)		—		—		—		—
Losses on equity securities	(2,321)		—		—		—		—		—		—		—
Gains on derivative financial instrument	—		—		—		—		71,800		—		—		—
Unrealized gains included in other comprehensive losses (2)	—		10,950		—		—		—		—		11,150		—
Unrealized gains included in earnings (3)	—		30,200		22,242		1,300		—		—		500		22,630

Settlement of forwards (4)	—		10,842		(10,842)		—		—		—		10,430		(10,430)
Transfer to Level 1 (5)	(40,692)		—		—		—		—		—		—		—
Redemption of debt securities	—		(31,250)		—		—		—		—		(31,250)		—
Balance at the end of the period	$	28,785	$	363,000	$	28,100	$	(8,100)	$	71,800	$	21,215	$	240,400	$	30,800

(3)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.

We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value of equity securities and the revenue participation right that we acquired from ApiJect Holdings, Inc. (“ApiJect”) in April 2022. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant in the event of a sale of the instruments, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 8–Non-Consolidated Affiliates for additional discussion.

We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of ~~March 31,~~June 30, 2022 ~~was based on~~by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding requires significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.

~~The~~We estimated the fair value of the Cytokinetics Funding Commitments as of ~~March 31,~~June 30, 2022 ~~was determined~~ using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty’s assumed cost of debt, which would impact Cytokinetics’ decision to exercise its option to draw on each respective tranche. This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of 30% and an assumed risk-adjusted discount rate of ~~13.2%~~15.2%. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.

In November 2021, we purchased 3,846 thousand shares of common stock inof BioCryst Pharmaceuticals, Inc. (“BioCryst”), calculated based on the volume-weighted average price of ~~BioCryst~~BioCryst’s common stock over a period preceding the closing of the transaction. As part of the transaction, we ~~are~~were restricted from selling the BioCryst common stock for six months following the close of the transaction. ~~The~~We determined the fair value of the BioCryst common stock as of ~~March 31, 2022 and~~ December 31, 2021 ~~was~~ based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the BioCryst common stock to match the duration of the transfer restriction. This methodology ~~incorporates~~incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which ~~requires~~required the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility ~~for the~~of BioCryst’s common stock, which would mean that the estimated fair value for the BioCryst common stock could be significantly higher or lower than the fair value determined by management at any particular date. During the three months ended June 30, 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset.

The fair value of the Development Funding Bond Forward as of ~~March 31,~~June 30, 2022 and December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. As of June 30, 2022, the Development Funding Bonds remain undrawn.

The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was based on the cash flows due to us from Biohaven of 2 times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following the FDA approval and starting one-year after FDA approval through the three months ended December 31, 2024. When the FDA approved Nurtec ODT in February 2020, we became entitled to receive a fixed payment amount of $250 million payable in equal quarterly payments between the three months ended March 31, 2021 and the three months ended December 31, 2024.

The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated that there is a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate of 13.7% and 9.5% as of June 30, 2022 and December 31, 2021, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.

The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of ~~March 31,~~June 30, 2022 and December 31, 2021 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than ~~the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value~~those determined ~~by management at any particular date. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected~~ by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.

The fair value of the Series A Biohaven Preferred Shares as of March 31, 2022 and December 31, 2021 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following the FDA approval and starting one-year after FDA approval, through the three months ended December 31, 2024. The FDA approved Nurtec ODT in February 2020, at which point we became entitled to receive a fixed payment amount of $250 million payable in equal quarterly payments between the three months ended March 31, 2021 and the three months ended December 31, 2024.

The fair value of the Series A Biohaven Preferred Shares as of March 31, 2022 and December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate of 10.5% and 9.5% as of March 31, 2022 and December 31, 2021, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.

On August 7, 2020, we entered into an expanded funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to accelerate the payment of any outstanding zavegepant milestone payments in a lump sum amount (“Milestone Acceleration Option”). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material in prior periods. As of June 30, 2022, the fair value of the Milestone Acceleration Option was $71.8 million, of which $63.2 million was recorded within Other current assets and $8.6 million was recorded within Other assets on the condensed consolidated balance sheet. For the three months ended June 30, 2022, we recorded $71.8 million of unrealized gain related to the change in the fair value of the Milestone Acceleration Option within (Gains)/losses on derivative financial instruments in the condensed consolidated statements of operations.

We estimated the fair value of the Milestone Acceleration Option as of June 30, 2022 using the “with-and-without” methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates, estimated probabilities of achieving the success-based milestones, and the probability that there will be a change of control event in different periods of time, which would result in accelerated milestone payments. Assessing the probability that there will be a change of control event, the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate, probabilities of achieving marketing approval, and our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.

Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of ~~third party~~third-party pricing services that either provide quoted market prices in active markets for identical or similar securities or observable inputs for their pricing without applying significant adjustments.

Financial royalty assets are measured and carried on the condensed consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. ~~The~~Management calculates the fair value of financial royalty assets ~~is calculated by management~~ using the forecasted royalty payments ~~we expect~~that are expected to ~~receive~~be received based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus sales ~~forecasts or, where~~forecasts. Where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of ~~our~~ financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of ~~our~~ financial royalty assets as of ~~March 31,~~June 30, 2022 and December 31, 2021 are presented below (in thousands):


			As of March 31, 2022								As of June 30, 2022
		Estimated Royalty Duration (1)	Gross Carrying Value		Cumulative Allowance for Changes in Expected Cash Flows (Note 6)		Net Carrying Value (5)			Estimated Royalty Duration (1)	Gross Carrying Value		Cumulative Allowance for Changes in Expected Cash Flows (Note 6)		Net Carrying Value (5)

Cystic fibrosis franchise	Cystic fibrosis franchise	2037 (2)	$	5,328,216	$	—	$	5,328,216	Cystic fibrosis franchise	2037 (2)	$	5,347,911	$	(54,609)	$	5,293,302
Tysabri	Tysabri	(3)	1,801,152		(30,613)		1,770,539		Tysabri	(3)	1,759,427		—		1,759,427
Imbruvica	Imbruvica	2027-2032	1,439,186		(345,780)		1,093,406		Imbruvica	2027-2032	1,439,443		(417,165)		1,022,278
Xtandi	Xtandi	2027-2028	1,081,587		(196,958)		884,629		Xtandi	2027-2028	1,053,621		(153,154)		900,467
Tremfya	Tremfya	2031-2032	869,596		—		869,596		Tremfya	2031-2032	876,834		—		876,834
Evrysdi	Evrysdi	2030-2035 (4)	736,665		(20,797)		715,868		Evrysdi	2030-2035 (4)	746,524		(1,992)		744,532
Other	Other	2020-2039	4,661,059		(1,024,195)		3,636,864		Other	2020-2040	4,824,393		(1,110,515)		3,713,878
Total	Total		$	15,917,461	$	(1,618,343)	$	14,299,118	Total		$	16,048,153	$	(1,737,435)	$	14,310,718
Less: Cumulative allowance for credit losses (Note 6)	Less: Cumulative allowance for credit losses (Note 6)						(261,223)		Less: Cumulative allowance for credit losses (Note 6)						(247,845)
Total financial royalty assets, net	Total financial royalty assets, net						$	14,037,895	Total financial royalty assets, net						$	14,062,873

(1)~~Dates~~Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.


			As of December 31, 2021								As of December 31, 2021
		Estimated Royalty Duration (1)	Gross Carrying Value		Cumulative Allowance for Changes in Expected Cash Flows (Note 6)		Net Carrying Value (5)			Estimated Royalty Duration (1)	Gross Carrying Value		Cumulative Allowance for Changes in Expected Cash Flows (Note 6)		Net Carrying Value (5)

Cystic fibrosis franchise	Cystic fibrosis franchise	2037 (2)	$	5,335,641	$	(48,636)	$	5,287,005	Cystic fibrosis franchise	2037 (2)	$	5,335,641	$	(48,636)	$	5,287,005
Tysabri	Tysabri	(3)	1,846,069		(16,617)		1,829,452		Tysabri	(3)	1,846,069		(16,617)		1,829,452
Imbruvica	Imbruvica	2027-2032	1,438,730		(236,871)		1,201,859		Imbruvica	2027-2032	1,438,730		(236,871)		1,201,859
Xtandi	Xtandi	2027-2028	1,100,065		(172,101)		927,964		Xtandi	2027-2028	1,100,065		(172,101)		927,964
Tremfya	Tremfya	2031-2032	881,671		—		881,671		Tremfya	2031-2032	881,671		—		881,671
Evrysdi	Evrysdi	2030-2035 (4)	727,774		—		727,774		Evrysdi	2030-2035 (4)	727,774		—		727,774
Other	Other	2020-2039	4,697,591		(909,916)		3,787,675		Other	2020-2040	4,697,591		(909,916)		3,787,675
Total	Total		$	16,027,541	$	(1,384,141)	$	14,643,400	Total		$	16,027,541	$	(1,384,141)	$	14,643,400
Less: Cumulative allowance for credit losses (Note 6)	Less: Cumulative allowance for credit losses (Note 6)						(310,804)		Less: Cumulative allowance for credit losses (Note 6)						(310,804)
Total financial royalty assets, net	Total financial royalty assets, net						$	14,332,596	Total financial royalty assets, net						$	14,332,596


	Activity for the Period
Balance at December 31, 2021 (1)	$	(1,694,945)

Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets	~~(319,191)~~(556,020)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets	~~84,989~~202,726

Current period provision for credit losses, net (2)	~~49,581~~62,959
Balance at ~~March 31,~~June 30, 2022	$	~~(1,879,566)~~(1,985,280)


As of March 31, 2022		Cost		Accumulated Amortization		Net Carrying Value
As of June 30, 2022								As of June 30, 2022	Cost		Accumulated Amortization		Net Carrying Value

DPP-IV patents	DPP-IV patents	$	606,216	$	606,216	$	—	DPP-IV patents	$	606,216	$	606,216	$	—

Total intangible royalty assets	Total intangible royalty assets	$	606,216	$	606,216	$	—	Total intangible royalty assets	$	606,216	$	606,216	$	—

~~Our revenue~~Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue ~~from royalty assets~~ is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate ~~our royalty~~such revenue from licensees based on the geography of the underlying sales as this ~~level of~~ information ismay not ~~always included in royalty reports~~be provided to ~~us. The marketers paying~~ us ~~royalties on these products do~~by marketers. For the three months ended June 30, 2022, revenue from intangible royalty assets was not ~~always provide, and are not necessarily required to provide, the breakdown of product sales by geography.~~material. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for ~~96% and 99%~~90% of ~~our~~ revenues from intangible royalty assets in the three months ended ~~March 31,~~June 30, 2021. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 93% and 94% of revenues from intangible royalty assets in the six months ended June 30, 2022 and 2021, respectively.

During the three months ended June 30, 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for our investments in ApiJect. We are also required to acquire additional common stock in ApiJect if certain milestones are achieved. The fair value of our equity investment was recorded within Equity securities and the fair value of the revenue participation right was recorded within Other assets on the condensed consolidated balance sheet as of June 30, 2022. No amounts were due from ApiJect as of June 30, 2022.

In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI.

The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this quarterly report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the three and six months ended ~~March 31,~~June 30, 2022, ~~and 2021,~~ we recorded an income ~~allocation~~allocations of ~~$4.5~~$4.7 million and ~~$5.2~~$9.3 million, respectively, within Equity in ~~(earnings)/losses~~earnings of equity method investees. During the three and six months ended June 30, 2021, we recorded income allocations of $25.6 million and $30.8 million, respectively, within Equity in earnings of equity method investees. We received cash distributions from the Legacy SLP Interest of ~~$7.3~~$6.8 million and ~~$3.9~~$14.1 million in the three and six months ended ~~March 31,~~June 30, 2022, respectively. We received cash distributions from the Legacy SLP Interest of $4.7 million and $8.6 million in the three and six months ended June 30, 2021, respectively.

We account for our partnership interests in Avillion Financing I, LP and its related entities (“Avillion I”), BAv Financing II, LP and its related entities (“Avillion II,” together with Avillion I, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the ~~entities.~~Avillion Entities. During the three and six months ended ~~March 31,~~June 30, 2022, we recorded a loss allocation from the Avillion Entities of $4.0 million and $8.2 million, respectively, within Equity in earnings of equity method investees. During the three and six months ended June 30, 2021, we recorded a loss allocation from the Avillion Entities of ~~$4.1~~$7.9 million and ~~$7.1~~$15.0 million, respectively, within Equity in ~~(earnings)/losses~~earnings of equity method investees.

On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. ~~Subsequent to the asset sale, the~~The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4 million during each of the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021, ~~in connection with Avillion I’s receipt of the fixed annual payments due under its co-development agreement with Pfizer.~~respectively.

In May 2018, RPIFT entered into an agreement, which was amended in July 2021 and was further amended in June 2022 to ~~invest up to $122.5~~increase the funding amount by $27.5 million, which totaled $150.0 million over multiple years in Avillion II, which is a party to a co-development agreement with AstraZeneca, ~~over multiple years~~ to fund a portion of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.

~~As of March 31, 2022 and December 31, 2021, RPIFT had $8.2 million and $11.2 million, respectively, of unfunded commitments related to the Avillion Entities.~~ Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments. As of June 30, 2022 and December 31, 2021, RPIFT had $35.7 million and $11.2 million, respectively, of unfunded commitments related to the Avillion Entities.

R&D funding expense consists of ~~upfront and ongoing development-stage funding~~ payments that we have made to counterparties to acquire royalties ~~and/~~or milestones on product candidates. ~~Upfront development-stage~~R&D funding expense includes ~~payments made at the close of acquisitions and subsequent milestone payments. Ongoing~~ development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. During the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021, we did not enter into any new ongoing R&D funding arrangements.

We recognized R&D funding expense of ~~$100.5~~$0.6 million and ~~$2.6~~$101.1 million ~~during~~for the three and six months ended ~~March 31,~~June 30, 2022, ~~and 2021,~~ respectively. We recognized R&D funding expense of $3.1 million and $5.8 million for the three and six months ended ~~March 31,~~June 30, 2021, respectively. During the six months ended June 30, 2022, R&D funding expense primarily related to upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product candidate. ~~R&D funding expense for the three months ended March 31, 2021 primarily related to ongoing R&D expenses under our co-funding agreement with Sanofi.~~


Type of Borrowing	Type of Borrowing	Date of Issuance	Maturity	March 31, 2022		December 31, 2021		Type of Borrowing	Date of Issuance	Maturity	As of June 30, 2022		As of December 31, 2021
Senior Unsecured Notes:	Senior Unsecured Notes:							Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)	$1,000,000, 0.75% (issued at 99.322% of par)	9/2020	9/2023	$	1,000,000	$	1,000,000	$1,000,000, 0.75% (issued at 99.322% of par)	9/2020	9/2023	$	1,000,000	$	1,000,000
$1,000,000, 1.20% (issued at 98.875% of par)	$1,000,000, 1.20% (issued at 98.875% of par)	9/2020	9/2025	1,000,000		1,000,000		$1,000,000, 1.20% (issued at 98.875% of par)	9/2020	9/2025	1,000,000		1,000,000
$1,000,000, 1.75% (issued at 98.284% of par)	$1,000,000, 1.75% (issued at 98.284% of par)	9/2020	9/2027	1,000,000		1,000,000		$1,000,000, 1.75% (issued at 98.284% of par)	9/2020	9/2027	1,000,000		1,000,000
$1,000,000, 2.20% (issued at 97.760% of par)	$1,000,000, 2.20% (issued at 97.760% of par)	9/2020	9/2030	1,000,000		1,000,000		$1,000,000, 2.20% (issued at 97.760% of par)	9/2020	9/2030	1,000,000		1,000,000
$600,000, 2.15% (issued at 98.263% of par)	$600,000, 2.15% (issued at 98.263% of par)	7/2021	9/2031	600,000		600,000		$600,000, 2.15% (issued at 98.263% of par)	7/2021	9/2031	600,000		600,000
$1,000,000, 3.30% (issued at 95.556% of par)	$1,000,000, 3.30% (issued at 95.556% of par)	9/2020	9/2040	1,000,000		1,000,000		$1,000,000, 3.30% (issued at 95.556% of par)	9/2020	9/2040	1,000,000		1,000,000
$1,000,000, 3.55% (issued at 95.306% of par)	$1,000,000, 3.55% (issued at 95.306% of par)	9/2020	9/2050	1,000,000		1,000,000		$1,000,000, 3.55% (issued at 95.306% of par)	9/2020	9/2050	1,000,000		1,000,000
$700,000, 3.35% (issued at 97.565% of par)	$700,000, 3.35% (issued at 97.565% of par)	7/2021	9/2051	700,000		700,000		$700,000, 3.35% (issued at 97.565% of par)	7/2021	9/2051	700,000		700,000

Unamortized debt discount and issuance costs	Unamortized debt discount and issuance costs			(198,862)		(203,930)		Unamortized debt discount and issuance costs			(193,801)		(203,930)
Total debt carrying value	Total debt carrying value			7,101,138		7,096,070		Total debt carrying value			7,106,199		7,096,070
Less: Current portion of long-term debt	Less: Current portion of long-term debt			—		—		Less: Current portion of long-term debt			—		—
Total long-term debt	Total long-term debt			$	7,101,138	$	7,096,070	Total long-term debt			$	7,106,199	$	7,096,070

On July 26, 2021, we issued $1.3 billion of senior unsecured notes (the “2021 Notes”) comprised of $600.0 million principal amount of notes due September 2031 and $700.0 million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, ~~beginning~~which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5 million and we capitalized approximately $12.3 million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes ~~have~~were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.

On September 2, 2020, we issued $6.0 billion of senior unsecured notes (the “2020 Notes” and, together with the 2021 Notes, the “Notes”). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0 million and we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes ~~have~~were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively.

The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.

On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”). The Credit Agreement ~~amends~~amended and ~~restates~~restated the ~~existing~~prior credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement ~~extends~~extended the maturity of the Revolving Credit Facility to September 15, 2026. As of ~~March 31,~~June 30, 2022 and December 31, 2021, there were no outstanding borrowings under the Revolving Credit Facility.

The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.

The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. If these financial covenants are not satisfied, the Credit Agreement prohibits us from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of ~~March 31,~~June 30, 2022, RP Holdings was in compliance with these covenants.

We have 2 classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has 1 vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. As of June 30, 2022, we had 437,139 thousand Class A ordinary shares and 170,081 thousand Class B ordinary shares outstanding.

An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a ~~one-for-one~~1-for-one basis for Class A ordinary shares on a quarterly basis. ~~As of March 31, 2022, we have outstanding 435,316 thousand Class A ordinary shares and 171,862 thousand Class B ordinary shares.~~ Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of ~~March 31,~~June 30, 2022, we ~~have~~had outstanding deferred shares of ~~363,521~~365,302 thousand.


		RPSFT		Legacy Investors Partnerships		Continuing Investors Partnerships (1)		EPA Holdings		Total			RPSFT		Legacy Investors Partnerships		Continuing Investors Partnerships		EPA Holdings		Total
December 31, 2021		$	13,528	$	1,809,269	$	2,649,154	$	—	$	4,471,951
March 31, 2022												March 31, 2022	$	8,409	$	1,756,269	$	2,599,646	$	—	$	4,364,324
Contributions	Contributions	—		1,970		1,353		—		3,323		Contributions	—		1,425		1,456		—		2,881
Distributions	Distributions	(10,260)		(104,201)		(34,515)		—		(148,976)		Distributions	(5,754)		(103,385)		(37,828)		—		(146,967)
Other exchanges	Other exchanges	—		—		(35,284)		—		(35,284)		Other exchanges	—		—		(26,938)		—		(26,938)
Net Income	Net Income	5,141		50,520		20,661		—		76,322		Net Income	6,227		61,642		119,224		—		187,093
Other comprehensive income/(loss):	Other comprehensive income/(loss):											Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities	Unrealized gains on available for sale debt securities	—		286		382		—		668		Unrealized gains on available for sale debt securities	—		1,639		2,163		—		3,802
Reclassification of unrealized gains on available for sale debt securities	Reclassification of unrealized gains on available for sale debt securities	—		(1,575)		(2,105)		—		(3,680)		Reclassification of unrealized gains on available for sale debt securities	—		(1,404)		(1,853)		—		(3,257)
March 31, 2022		$	8,409	$	1,756,269	$	2,599,646	$	—	$	4,364,324
June 30, 2022												June 30, 2022	$	8,882	$	1,716,186	$	2,655,870	$	—	$	4,380,938


	RPSFT		Legacy Investors Partnerships		Continuing Investors Partnerships		EPA Holdings		Total
December 31, 2021	$	13,528	$	1,809,269	$	2,649,154	$	—	$	4,471,951
Contributions	—		3,395		2,808		—		6,203
Distributions	(16,013)		(207,586)		(72,343)		—		(295,942)
Other exchanges	—		—		(62,222)		—		(62,222)
Net Income	11,367		112,162		139,886		—		263,415
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities	—		1,925		2,545		—		4,470
Reclassification of unrealized gains on available for sale debt securities	—		(2,979)		(3,958)		—		(6,937)
June 30, 2022	$	8,882	$	1,716,186	$	2,655,870	$	—	$	4,380,938


	RPSFT		Legacy Investors Partnerships		Continuing Investors Partnerships		EPA Holdings		Total
March 31, 2021	$	13,841	$	1,882,655	$	3,058,322	$	—	$	4,954,818
Contributions	—		6,654		4,865		—		11,519
Distributions	(12,476)		(127,747)		(30,585)		—		(170,808)
Other exchanges	—		—		(486,591)		—		(486,591)
Net income	19,275		133,743		212,961		—		365,979
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities	—		1,059		1,618		—		2,677
Reclassification of unrealized gains on available for sale debt securities	—		(2,337)		(3,571)		—		(5,908)
June 30, 2021	$	20,640	$	1,894,027	$	2,757,019	$	—	$	4,671,686


	RPSFT		Legacy Investors Partnerships		Continuing Investors Partnerships		EPA Holdings		Total
December 31, 2020	$	12,436	$	1,939,509	$	3,125,091	$	—	$	5,077,036
Contributions	—		9,907		4,865		—		14,772
Distributions	(26,129)		(222,289)		(67,768)		—		(316,186)
Other exchanges	—		—		(551,663)		—		(551,663)
Net income	34,333		170,000		251,506		—		455,839
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities	—		1,960		3,130		—		5,090
Reclassification of unrealized gains on available for sale debt securities	—		(5,060)		(8,142)		—		(13,202)
June 30, 2021	$	20,640	$	1,894,027	$	2,757,019	$	—	$	4,671,686

The Continuing Investors Partnerships’ ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of ~~March 31,~~June 30, 2022, ofthe Continuing Investors Partnerships owned approximately 28% of RP Holdings ~~through their ownership of the RP Holdings Class B Interests. Royalty Pharma plc owns~~with the remaining 72% ~~of RP Holdings through its ownership of RP Holdings Class A Interests and RP Holdings Class B Interests as of March 31, 2022.~~

RPSFT Legacy Investors Partnerships Continuing Investors Partnerships (1) EPA Holdings Total
December 31, 2020 $ 12,436 $ 1,939,509 $ 3,125,091 $ — $ 5,077,036
Contributions — 3,253 — — 3,253
Distributions (13,653) (94,542) (37,183) — (145,378)
Other exchanges — — (65,072) — (65,072)
Net income 15,058 36,257 38,545 — 89,860
Other comprehensive income:
Unrealized gains on available for sale debt securities — 901 1,512 — 2,413
Reclassification of unrealized gains on available for sale debt securities — (2,723) (4,571) — (7,294)
March 31, 2021 $ 13,841 $ 1,882,655 $ 3,058,322 $ — $ 4,954,818

EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period ~~will be~~are grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests ~~for which we~~that will ~~issue the same number of Class B ordinary shares, which may~~ be ~~subsequently~~ exchanged upon issuance for ~~our~~ Class A ordinary shares. We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met.

The holders of Class A ordinary shares are entitled to receive dividends subject to approval by ~~the~~our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. In the ~~three~~six months ended ~~March 31,~~June 30, 2022, we declared and paid ~~one~~two quarterly cash ~~dividend~~dividends of $0.19 per Class A ordinary share for an aggregate amount of ~~$82.3~~$165.3 million to holders of our Class A ordinary shares. In the ~~three~~six months ended ~~March 31,~~June 30, 2021, we declared and paid ~~one~~two quarterly cash ~~dividend~~dividends of $0.17 per Class A ordinary share for an aggregate amount of ~~$66.0~~$138.6 million to holders of our Class A ordinary shares.

We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized ~~based on estimated fair value of the award on the grant date and amortized~~ on a straight-line basis over the requisite service period of generally one year as part of General and administrative expenses in the condensed consolidated statements of operations. ~~We recognized share-based compensation expense of approximately $0.7 million and $0.9 million for~~In the three and six months ended ~~March 31,~~June 30, 2022 and 2021, ~~respectively.~~respectively, we did not recognize material share-based compensation expenses.

Basic earnings per share (“EPS”) is ~~computed~~calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is ~~computed~~calculated by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares and deferred shares under the two-class method has not been presented.

Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a 1-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs. For the three and six months ended ~~March 31,~~June 30, 2022 and 2021, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact.


			For the Three Months Ended March 31,					For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2022		2021			2022				2021				2022			2021
Numerator	Numerator											Numerator
Consolidated net income	Consolidated net income				$	128,083			$	158,979		Consolidated net income	$	491,597		$	806,755		$	619,680	$	965,734
Less: Net income attributable to Continuing Investors Partnerships	Less: Net income attributable to Continuing Investors Partnerships				20,661				38,545			Less: Net income attributable to Continuing Investors Partnerships	119,224			212,961			139,886		251,506
Less: Net income attributable to Legacy Investors Partnerships and RPSFT	Less: Net income attributable to Legacy Investors Partnerships and RPSFT				55,661				51,315			Less: Net income attributable to Legacy Investors Partnerships and RPSFT	67,869			153,018			123,529		204,333
Net income attributable to Royalty Pharma plc - basic	Net income attributable to Royalty Pharma plc - basic				51,761				69,119			Net income attributable to Royalty Pharma plc - basic	304,504			440,776			356,265		509,895
Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares	Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares				20,661				38,545			Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares	119,224			212,961			139,886		251,506
Net income attributable to Royalty Pharma plc - diluted	Net income attributable to Royalty Pharma plc - diluted				$	72,422			$	107,664		Net income attributable to Royalty Pharma plc - diluted	$	423,728		$	653,737		$	496,151	$	761,401

Denominator	Denominator											Denominator
Weighted average Class A ordinary shares outstanding - basic	Weighted average Class A ordinary shares outstanding - basic				433,956				389,760			Weighted average Class A ordinary shares outstanding - basic	436,318			409,344			435,144		399,606
Add: Dilutive effects as shown separately below	Add: Dilutive effects as shown separately below											Add: Dilutive effects as shown separately below
Class B ordinary shares exchangeable for Class A ordinary shares	Class B ordinary shares exchangeable for Class A ordinary shares				173,220				217,350			Class B ordinary shares exchangeable for Class A ordinary shares	170,864			197,773			172,035		207,508
Unvested RSUs	Unvested RSUs				25				38			Unvested RSUs	32			46			28		37
Weighted average Class A ordinary shares outstanding - diluted	Weighted average Class A ordinary shares outstanding - diluted				607,201				607,148			Weighted average Class A ordinary shares outstanding - diluted	607,214			607,163			607,207		607,151

Earnings per Class A ordinary share - basic	Earnings per Class A ordinary share - basic				$	0.12			$	0.18		Earnings per Class A ordinary share - basic	$	0.70		$	1.08		$	0.82	$	1.28
Earnings per Class A ordinary share - diluted	Earnings per Class A ordinary share - diluted				$	0.12			$	0.18		Earnings per Class A ordinary share - diluted	$	0.70		$	1.08		$	0.82	$	1.25


		For the Three Months Ended March 31,					For the Six Months Ended June 30,
		2022		2021			2022		2021
Cash flow from operating activities:	Cash flow from operating activities:					Cash flow from operating activities:
Consolidated net income	Consolidated net income	$	128,083	$	158,979	Consolidated net income	$	619,680	$	965,734
Adjustments to reconcile consolidated net income to net cash provided by operating activities:	Adjustments to reconcile consolidated net income to net cash provided by operating activities:					Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Income from financial royalty assets	Income from financial royalty assets	(511,523)		(529,625)		Income from financial royalty assets	(1,026,873)		(1,033,039)
Provision for changes in expected cash flows from financial royalty assets	Provision for changes in expected cash flows from financial royalty assets	184,621		292,262		Provision for changes in expected cash flows from financial royalty assets	290,335		48,499
Amortization of intangible assets	Amortization of intangible assets	5,670		5,671		Amortization of intangible assets	5,670		11,404
Amortization of debt discount and issuance costs	Amortization of debt discount and issuance costs	5,343		4,790		Amortization of debt discount and issuance costs	10,683		9,583

Losses on derivative financial instruments		—		2,555
Losses on equity securities		36,162		54,186
Equity in (earnings)/losses of equity method investees		(397)		1,918
(Gains)/losses on derivative financial instruments						(Gains)/losses on derivative financial instruments	(71,805)		4,464
Losses/(gains) on equity securities						Losses/(gains) on equity securities	28,138		(1,309)
Equity in earnings of equity method investees						Equity in earnings of equity method investees	(1,134)		(15,783)

Distributions from equity method investees	Distributions from equity method investees	20,690		17,325		Distributions from equity method investees	27,502		22,003

Share-based compensation	Share-based compensation	496		713		Share-based compensation	1,005		1,434
Interest income accretion	Interest income accretion	(8,954)		(15,491)		Interest income accretion	(16,942)		(28,790)
Unrealized losses/(gains) on available for sale debt securities		16,579		(9,115)
Unrealized gains on available for sale debt securities						Unrealized gains on available for sale debt securities	(53,742)		(23,130)

Other	Other	1,523		958		Other	2,657		2,049
Decrease/(increase) in operating assets:	Decrease/(increase) in operating assets:					Decrease/(increase) in operating assets:
Cash collected on financial royalty assets	Cash collected on financial royalty assets	621,689		573,946		Cash collected on financial royalty assets	1,181,354		1,094,094

Accrued royalty receivable	Accrued royalty receivable	2,096		(299)		Accrued royalty receivable	35,254		(988)

Other royalty income receivable	Other royalty income receivable	405		(530)		Other royalty income receivable	(2,292)		(4,683)
Other current assets and other assets	Other current assets and other assets	1,242		1,939		Other current assets and other assets	2,711		3,703
Increase/(decrease) in operating liabilities:	Increase/(decrease) in operating liabilities:					Increase/(decrease) in operating liabilities:
Accounts payable and accrued expenses	Accounts payable and accrued expenses	1,042		(2,207)		Accounts payable and accrued expenses	6,555		(913)
Interest payable	Interest payable	(44,497)		(31,875)		Interest payable	(3,534)		758

Other current liabilities						Other current liabilities	—		2,730

Net cash provided by operating activities	Net cash provided by operating activities	$	460,270	$	526,100	Net cash provided by operating activities	$	1,035,222	$	1,057,820

As of ~~March 31,~~June 30, 2022, $250 million of the Cytokinetics Commercial Launch Funding remained unfunded. Cytokinetics is required to draw ~~$25~~$50 million if a certain contingency is met and has the option to draw the remaining ~~$225~~$200 million upon the occurrence of certain regulatory and clinical development milestones. As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022.

We have commitments to advance funds to counterparties through our investment in the Avillion ~~Entities and R&D arrangements.~~Entities. Please refer to Note 8–Non-Consolidated Affiliates ~~and Note 9– Research & Development (“R&D”) Funding Expense, respectively,~~ for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the ~~management agreement~~Management Agreement as described in Note 15–Related Party Transactions, which are variable and primarily based on cash receipts.

In the ordinary course of ~~its~~our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such ~~proceedings~~occurrences taking place in the future is remote.

We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings inon our condensed consolidated balance sheets as of ~~March 31,~~June 30, 2022 and December 31, 2021. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.

In connection with the Exchange Offer Transactions (discussed in Note 1– Organization and Purpose), the Manager entered into management agreements with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreement, we pay quarterly operating and personnel expenses to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected inon our consolidated net income, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months.

During the three and six months ended ~~March 31,~~June 30, 2022, ~~and 2021,~~ total operating and personnel payments incurred were ~~$41.2~~$36.0 million and ~~$35.7~~$77.2 million, respectively, including the amounts attributable to Old RPI, and were recognized within General and administrative expenses onin the condensed consolidated statements of operations. During the three and six months ended June 30, 2021, total operating and personnel payments incurred were $32.4 million and $68.1 million, respectively, including the amounts attributable to Old RPI, and were recognized within General and administrative expenses in the condensed consolidated statements of operations.


		As of March 31, 2022		As of December 31, 2021			As of June 30, 2022		As of December 31, 2021
Due to Legacy Investors Partnerships	Due to Legacy Investors Partnerships	$	102,179	$	92,608	Due to Legacy Investors Partnerships	$	107,886	$	92,608
Due to RPSFT	Due to RPSFT	13,831		15,326		Due to RPSFT	8,104		15,326
Total distributions payable to non-controlling interests	Total distributions payable to non-controlling interests	$	116,010	$	107,934	Total distributions payable to non-controlling interests	$	115,990	$	107,934

In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement.

Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI Inc. (“MSCI”). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI’s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI’s revenues from those indexes. No amounts were due from MSCI as of both ~~March 31,~~June 30, 2022 and December 31, 2021. The financial impact associated with this transaction has not been material to date.

In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 8–Non-Consolidated Affiliates for additional ~~discussion.~~discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.

Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.

In July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance Biopharma, Inc. (“Theravance”) and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy. We made an upfront payment of $1.31 billion in July 2022 and committed up to $300 million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25 million in upfront funding and a potential $15 million regulatory milestone payment to support the clinical development of ampreloxetine.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand our results of operations and financial condition, cash flows and other changes in financial condition. MD&A is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements and the accompanying notes to our consolidated financial statements included in our Annual Report on Form 10-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Special Note Regarding Forward-Looking Statements included elsewhere in this Quarterly Report on Form 10-Q and in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K.

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, which includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, ~~Biogen’s Tysabri,~~GSK’s Trelegy, Novartis’ Promacta, Biohaven and Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi,Gilead’s Trodelvy, ~~Merck & Co.’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko~~ and ~~Trikafta, and ten~~11 development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry.

•~~Synthetic/Hybrid Royalties~~Synthetic Royalties/R&D Funding – Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone ~~payments, or be structured as a long-term stream of fixed payments with a predetermined schedule. In many of our synthetic royalties, we may~~payments. We also ~~make investments in the public equity of the company, where the main value driver of the company is the product on which we concurrently acquired a royalty.~~

•Launch and Development Capital – Tailored supplemental funding solutions, generally included as a component within a transaction, increasing the scale of our capital. Launch and development capital is generally provided in exchange for a long-term stream of fixed payments with a predetermined schedule around the launch of a drug. Launch and development capital may also ~~made upfront development-stage funding payments to biotechnology companies to acquire royalties and/or milestones on development-stage product candidates.~~include a direct investment in the public equity of a company.

•Mergers and Acquisitions (“M&A”) Related – We acquire royalties in connection with M&A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.

~~In connection with our IPO, we~~We consummated an exchange offer on February 11, ~~2020.~~2020 to facilitate our IPO. Through the exchange offer, investors ~~representing~~which represented 82% of the aggregate limited partnership in the various partnerships (the “Legacy Investors Partnerships”) that ~~own~~owned Royalty Pharma Investments, an Irish unit trust (“Old RPI”), exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in RPI US Partners 2019, LP, a Delaware limited partnership or RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”). The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under senior credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer ~~Transactions”.~~Transactions.”

~~Following our IPO, we operate and~~We control ~~the business affairs of~~ Royalty Pharma Holdings Ltd (“RP Holdings”) through our ~~controlling~~ ownership of RP Holdings’ Class A ordinary shares ~~(the “RP Holdings Class A Interests”)~~ and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). RP Holdings is the sole owner of RPI 2019 ICAV, which is an Irish collective asset management entity formed to facilitate our Exchange Offer ~~Transactions.~~Transactions, and is the successor to Old RPI.

Most of the royalties we acquire are treated as investments in cash flow streams and are classified as financial assets measured under the effective interest method in accordance with generally accepted accounting principles in the United States (“GAAP”). Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset.

The measurement of income from our financial royalty assets requires significant judgments and estimates, including management’s judgment in forecasting the expected future cash flows of the underlying royalties and the expected duration of the financial royalty asset. Our cash flow forecasts are generated and updated each reporting period by manually compiling sell-side equity research analysts’ consensus sales estimates for each of the products in which we own royalties. We then calculate our expected royalty cash flows using these consensus sales forecasts. In any given reporting period, any decline or increase in the expected future cash flows associated with a financial royalty asset is recognized in our income statement as non-cash provision expense or provision income, respectively.

As a result of the non-cash charges associated with applying the effective interest method accounting methodology, our income statement activity can be volatile and unpredictable. Small declines in sell-side equity research analysts’ consensus sales forecasts over a long term horizon can result in an immediate non-cash income statement expense recognition which generates a corresponding cumulative allowance that reduces the gross asset balance, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise royalty and beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expense. Over the course of 10 quarters, we recognized non-cash provision expense as a result of these changes in forecasts including non-cash provision expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017 related to this financial royalty asset. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts’ consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty. While small reductions in the cumulative allowance for the cystic fibrosis franchise were recognized as provision income over the course of 2017 and 2018, there remained a $1.10 billion cumulative allowance that was fully reduced by recognizing provision income of $1.10 billion in 2019 as a result of an increase in sell-side equity research analysts’ consensus sales forecasts associated with the Trikafta approval. This example illustrates the volatility caused by our accounting model.

In addition, due to the nature of our effective interest methodology, there is no direct correlation between our income from financial royalty assets and our royalty receipts. Therefore, management believes investors should not look to income from royalties and the associated provision for changes in future cash flows as a measure of our near-term financial performance or as a source for predicting future income or growth trends. Our operations have historically been financed primarily with cash flows generated by our royalties. Given the importance of cash flows and their predictability to management’s operation of the business, management uses royalty receipts as the primary measure of our operating performance. Royalty receipts refer to the summation of the following line items from our GAAP consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees.

In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. The closest comparable GAAP measure to each of the non-GAAP measures that management review is Net cash provided by operating activities. The key non-GAAP metrics we focus on are Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow, each of which is further discussed in the section titled “Non-GAAP Financial ~~Results”.~~Results.”

Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of ~~the~~our strength ~~of the Company~~ and the performance of the business. Management uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, which is derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants.

Our portfolio consists of royalties on more than 35 marketed therapies and ~~ten~~11 development-stage product candidates. The therapies in our portfolio address therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology and diabetes, and are delivered to patients across both primary and specialty care settings. The table below includes royalty receipts for the three and six months ended ~~March 31,~~June 30, 2022 and 2021 by product in order of ~~contributions~~contribution to royalty receipts for the ~~three~~six months ended ~~March 31,~~June 30, 2022 (in thousands).


Royalties	Royalties	Marketer(s)		Therapeutic Area		For the Three Months Ended March 31,				Royalties				Marketer(s)				Therapeutic Area			For the Three Months Ended June 30,						For the Six Months Ended June 30,
							2022		2021								Therapeutic Area				2022			2021			2022				2021

Cystic fibrosis franchise (1)	Cystic fibrosis franchise (1)		Vertex		Rare disease					$	201,882							$	166,809	Cystic fibrosis franchise (1)			Vertex			Rare disease			$	181,968			$	156,023			$	383,851	$	322,832
Tysabri	Tysabri	Biogen		Neurology				97,439				86,921				Tysabri			Biogen			Neurology			93,128			92,070				190,567				178,991
Imbruvica	Imbruvica	AbbVie, Johnson & Johnson		Cancer				87,171				89,135			Imbruvica			AbbVie, Johnson & Johnson			Cancer			80,381			87,289				167,552				176,424
Xtandi															Xtandi			Pfizer, Astellas			Cancer			51,988			35,767				95,383				76,812
Promacta	Promacta	Novartis		Hematology				47,897				44,126			Promacta			Novartis			Hematology			34,715			32,341				82,612				76,466
Xtandi		Pfizer, Astellas		Cancer				43,395				41,045
Januvia, Janumet, Other DPP-IVs (2)	Januvia, Janumet, Other DPP-IVs (2)	Merck & Co., others		Diabetes				35,682				35,761			Januvia, Janumet, Other DPP-IVs (2)			Merck & Co., others			Diabetes			35,695			39,438				71,377				75,200

Tremfya	Tremfya	Johnson & Johnson		Immunology				28,224				—			Tremfya			Johnson & Johnson			Immunology			18,428			—				46,653				—
Nurtec ODT/Biohaven payment (3)	Nurtec ODT/Biohaven payment (3)	Biohaven, Pfizer		Neurology				20,375				16,501			Nurtec ODT/Biohaven payment (3)			Biohaven, Pfizer			Neurology			18,715			16,721				39,090				33,222
Cabometyx/Cometriq	Cabometyx/Cometriq	Exelixis, Ipsen, Takeda		Cancer				12,857				—			Cabometyx/Cometriq			Exelixis, Ipsen, Takeda			Cancer			13,055			10,129				25,911				10,129
Farxiga/Onglyza	Farxiga/Onglyza	AstraZeneca		Diabetes				9,469				8,562			Farxiga/Onglyza			AstraZeneca			Diabetes			11,346			9,113				20,815				17,675
Evrysdi	Evrysdi	Roche		Rare disease				9,197				1,677			Evrysdi			Roche			Rare disease			8,134			2,971				17,331				4,648
Prevymis															Prevymis			Merck & Co.			Infectious disease			9,997			8,772				14,123				17,402
Trodelvy	Trodelvy	Gilead		Cancer				4,892				2,605			Trodelvy			Gilead			Cancer			6,040			2,992				10,932				5,597
Erleada	Erleada	Johnson & Johnson		Cancer				4,886				3,104			Erleada			Johnson & Johnson			Cancer			4,834			3,116				9,720				6,220
Emgality		Lilly		Neurology				4,764				3,264
Crysvita	Crysvita	Ultragenyx, Kyowa Kirin		Rare disease				4,712				3,588			Crysvita			Ultragenyx, Kyowa Kirin			Rare disease			4,933			3,929				9,645				7,516
Orladeyo	Orladeyo	BioCryst		Rare disease				4,426				12			Orladeyo			BioCryst			Rare disease			4,765			957				9,191				969
Prevymis		Merck & Co.		Infectious disease				4,126				8,630
Emgality															Emgality			Lilly			Neurology			4,425			3,550				9,188				6,814

Oxlumo	Oxlumo	Alnylam		Rare disease				766				—			Oxlumo			Alnylam			Rare disease			583			—				1,349				—
Other products (4)	Other products (4)							88,871				137,738			Other products (4)									50,038			82,502				138,909				220,241
Total royalty receipts	Total royalty receipts							$	711,031			$	649,478		Total royalty receipts									$	633,168		$	587,680			$	1,344,199			$	1,237,158

(3)~~Includes royalty receipts for Nurtec ODT of $4.8 million and $0.9 million for the three months ended March 31, 2022 and 2021, respectively, and~~We have received quarterly ~~redemptions~~redemption payments of $15.6 million beginning in ~~2022 and~~the first quarter of 2021 ofrelated to the Series A Biohaven Preferred Shares (presented as Proceeds from available for sale debt securities on the statements of cash flows). The remaining cash receipts related to royalty receipts from Nurtec ODT.

(4)Other products primarily include royalty receipts on the following products: Bosulif (a product co-developed by our joint venture investee, AvillionI, for which receipts are presented as Distributions from equity method investees on the statements of cash flows), Cimzia, Entyvio, HIV franchise, IDHIFA, Letairis, Lexiscan, Mircera, Myozyme, Nesina, Soliqua, Tazverik and contributions from the Legacy SLP Interest (defined below).

2. The RP Holdings Class B Interests held indirectly by the Continuing Investors Partnerships, which represent an approximate 28% ownership interest in RP Holdings as of ~~March 31,~~June 30, 2022 and are exchangeable for our Class A ordinary shares. The value of this non-controlling interest will decline over time if the investors who indirectly own the RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares.

~~Following the IPO,~~ EPA Holdings is entitled to receive Equity Performance Awards through its RP Holdings Class C Special Interest. Equity Performance Awards owed to EPA Holdings will be recognized as an equity transaction when the obligation becomes due and will impact the income allocated to non-controlling interest related to the RP Holdings Class C Special ~~Interest at that time.~~Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests ~~for which we~~that will ~~issue the same number of our Class B ordinary shares, which may~~ be ~~subsequently~~ exchanged upon issuance for ~~our~~ Class A ordinary shares. We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions are met, which we do not expect to occur until the mid-2020s.

Total income and other revenues is primarily comprised of income from our financial royalty assets, royalty revenue from our intangible royalty assets, and royalty income generally arising from successful commercialization of products developed through ~~joint~~ R&D funding arrangements. Most of our royalties on both approved products and development-stage product candidates that are not accounted for as R&D funding expense are classified as financial assets as our ownership rights are generally passive in nature. In instances in which we acquire a royalty that does include more substantial rights or ownership of the underlying intellectual property, we classify such royalties as intangible assets.

We recognize interest income related to our financial royalty assets. Royalty revenue relates solely to revenue from our DPP-IV ~~patent estate~~products for which the patent rights have been licensed to various counterparties. For the three and six months ended ~~March 31,~~June 30, 2022 and 2021, the royalty payors accounting for greater than 10% of our total income and other revenues in any one period are shown in the table below:


			For the Three Months Ended March 31,					For the Three Months Ended June 30,			For the Six Months Ended June 30,
Royalty Payor	Royalty Payor	Royalties		2022		2021			Royalty Payor	Royalties	2022		2021		2022		2021
Vertex	Vertex	Cystic fibrosis franchise		35	%	32	%		Vertex	Cystic fibrosis franchise	38	%	33	%	36	%	33	%
AbbVie	AbbVie	Imbruvica		16	%	17	%		AbbVie	Imbruvica	15	%	17	%	15	%	17	%
Gilead		HIV franchise, Letairis, Lexiscan, Trodelvy		*		12	%

Our financial royalty assets represent investments in cash flow streams with yield components that most closely resemble loans measured at amortized cost under the effective interest method. We calculate the effective interest rate using forecasted expected cash flows to be received over the life of the royalty asset relative to the initial acquisition price. Interest income is recognized at the effective rate of return over the expected life of the asset, which is calculated at the end of each reporting period and applied prospectively. As changes in sell-side equity research analysts’ consensus sales estimates are updated on a quarterly basis, the effective rate of return changes. For example, if sell-side equity research analysts’ consensus sales forecasts increase, the yield to derive income on a financial royalty asset will increase and result in higher income for subsequent periods.

Variables affecting the recognition of interest income from financial royalty assets on individual products under the prospective effective interest method include any one of the following: (1) additional acquisitions, (2) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts’ consensus sales forecasts, (3) regulatory approval of additional indications which leads to new cash flow streams, (4) changes to the estimated duration of the royalty (i.e., patent expiration date) and (5) changes in amounts and timing of projected royalty receipts and milestone payments. Our financial royalty assets are directly linked to sales of underlying pharmaceutical products whose life cycle typically peaks at a point in time, followed frequently by declining sales trends due to the entry of generic competition, resulting in natural declines in the asset balance and periodic interest income over the life of our royalties. The recognition of interest income from royalties requires management to make estimates and assumptions around many factors, including those impacting the variables noted above.

Other royalty income primarily includes income from financial royalty assets that have been fully amortized by the expected ~~expiry~~expiration date and royalty income from synthetic royalties arising out of R&D funding arrangements. Occasionally, a royalty asset may be amortized on an accelerated basis due to collectability concerns, which, if resolved, may result in future cash collections when no financial royalty asset remains. Similarly, we may continue to collect royalties on a financial royalty asset beyond the estimated duration by which the financial asset was fully amortized. In each scenario where a financial royalty asset has been fully amortized, income from such royalty is recognized as Other royalty income. Other royalty income also includes income from royalties that are recorded at fair value on our condensed consolidated balance sheets.

As discussed above, income is accreted on our financial royalty assets using the effective interest method. As we update our forecasted cash flows on a periodic basis and recalculate the present value of the remaining future cash flows, any shortfall when compared to the carrying value of the financial royalty asset is recorded directly to the income statement through the line item Provision for changes in expected cash flows from financial royalty assets. If, in a subsequent period, there is an increase in expected cash flows or if actual cash flows are greater than cash flows previously expected, we reduce the cumulative allowance previously established for a financial royalty asset for the incremental increase in the present value of cash flows expected to be collected. This results in provision income (i.e., a credit to the provision).

Most of the same variables and management’s estimates affecting the recognition of interest income on our financial royalty assets also impact the provision. In any period, we will recognize provision income or expense as a result of the following factors: (1) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts’ consensus sales forecasts, (2) regulatory approval of additional indications which leads to new cash flow streams, (3) changes to the estimated duration of the royalty (i.e., patent expiration date) and (4) changes in amounts and timing of projected royalty receipts and milestone payments.

R&D funding expense consists of ~~upfront and ongoing development-stage funding~~ payments that we have made to counterparties to acquire royalties ~~and/~~or milestones on ~~development-stage~~ product ~~candidates. Upfront development-stage funding expense~~candidates, and includes ~~payments made at the close of acquisitions and subsequent milestone payments. Ongoing~~ development-stage funding payments that are made upfront or upon pre-approval milestones, and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. These expenditures relate to the activities performed by our counterparties to develop and test new products, to test existing products for treatment in new indications, and to ensure product efficacy and regulatory compliance prior to launch.

Under the management ~~agreement that became effective on February 11, 2020 (the~~agreements (collectively, the “Management Agreement”), we pay quarterly operating and personnel expenses to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the cash receipts from royalty investments for ~~each~~such quarter and 0.25% of the value of our security investments under GAAP as of the end of ~~each~~such quarter.

The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in G&A expenses, are calculated as the greater of $1 million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investors Partnerships) during the previous twelve calendar months.

1. Legacy SLP Interest. In connection with the Exchange Offer Transactions, we acquired an equity method investment from the Continuing Investors Partnerships in the form of a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) in exchange for issuing shares in our subsidiary. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and a performance income allocation on a similar basis. As the Legacy Investors Partnerships no longer participate in investment opportunities, the value of the Legacy SLP Interest is expected to decline over time.

2. The Avillion Entities. The Avillion ~~entities~~Entities (as defined below) partner with global biopharmaceutical companies to perform R&D in exchange for success-based milestones ~~and/or~~and royalties ~~once~~if products are commercialized. Our investments in Avillion Financing I, LP (“Avillion I”) and BAv Financing II, LP (“Avillion II”, or, together with Avillion I, the “Avillion Entities”) are accounted for using the equity method.

Net income attributable to non-controlling interests includes the RP Holdings Class B Interests held by the Continuing Investors Partnerships and will include net income attributable to the RP Holdings Class C Special Interest held by EPA Holdings once certain conditions have been met. Future net income attributable to the non-controlling interest related to the RP Holdings Class B Interests held by the Continuing Investors Partnerships will decline over time if the investors who indirectly own the RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares.


(in thousands)	(in thousands)	For the Three Months Ended March 31,	2022 vs. 2021 Change				(in thousands)	For the Three Months Ended June 30,						Change				For the Six Months Ended June 30,				Change
			2022		2021				$		%			2022		2021		$		%		2022		2021		$		%
Income and other revenues:	Income and other revenues:												Income and other revenues:
Income from financial royalty assets	Income from financial royalty assets		$	511,523	$	529,625			$	(18,102)	(3.4)	%	Income from financial royalty assets	$	515,350	$	503,414	$	11,936	2.4	%	$	1,026,873	$	1,033,039	$	(6,166)	(0.6)	%
Revenue from intangible royalty assets	Revenue from intangible royalty assets		33,586		36,061				(2,475)		(6.9)	%	Revenue from intangible royalty assets	2,537		40,127		(37,590)		(93.7)	%	36,123		76,188		(40,065)		(52.6)	%
Other royalty income	Other royalty income		16,940		7,341				9,599		130.8	%	Other royalty income	18,068		11,422		6,646		58.2	%	35,008		18,763		16,245		86.6	%
Total income and other revenues	Total income and other revenues		562,049		573,027				(10,978)		(1.9)	%	Total income and other revenues	535,955		554,963		(19,008)		(3.4)	%	1,098,004		1,127,990		(29,986)		(2.7)	%
Operating expenses:	Operating expenses:												Operating expenses:
Provision for changes in expected cash flows from financial royalty assets	Provision for changes in expected cash flows from financial royalty assets		184,621		292,262				(107,641)		(36.8)	%	Provision for changes in expected cash flows from financial royalty assets	105,714		(243,762)		349,476		(143.4)	%	290,335		48,499		241,836		*
Research and development funding expense	Research and development funding expense		100,500		2,641				97,859		*		Research and development funding expense	606		3,122		(2,516)		(80.6)	%	101,106		5,763		95,343		*
Amortization of intangible assets	Amortization of intangible assets		5,670		5,671				(1)		0.0	%	Amortization of intangible assets	—		5,733		(5,733)		(100.0)	%	5,670		11,404		(5,734)		(50.3)	%
General and administrative expenses	General and administrative expenses		51,540		43,156				8,384		19.4	%	General and administrative expenses	51,843		44,921		6,922		15.4	%	103,383		88,077		15,306		17.4	%

Total operating expenses, net			342,331		343,730				(1,399)		(0.4)	%
Total operating expenses/(income), net													Total operating expenses/(income), net	158,163		(189,986)		348,149		(183.2)	%	500,494		153,743		346,751		225.5	%
Operating income	Operating income		219,718		229,297				(9,579)		(4.2)	%	Operating income	377,792		744,949		(367,157)		(49.3)	%	597,510		974,247		(376,737)		(38.7)	%
Other (income)/expense:	Other (income)/expense:												Other (income)/expense:
Equity in (earnings)/losses of equity method investees			(397)		1,918				(2,315)		(120.7)	%
Equity in earnings of equity method investees													Equity in earnings of equity method investees	(737)		(17,701)		16,964		(95.8)	%	(1,134)		(15,783)		14,649		(92.8)	%
Interest expense	Interest expense		47,063		37,415				9,648		25.8	%	Interest expense	46,966		37,426		9,540		25.5	%	94,029		74,841		19,188		25.6	%

Other expense, net			44,969		30,985				13,984		45.1	%
Total other expenses, net			91,635		70,318				21,317		30.3	%
Other income, net													Other income, net	(160,034)		(81,531)		(78,503)		96.3	%	(115,065)		(50,545)		(64,520)		127.6	%
Total other (income)/expenses, net													Total other (income)/expenses, net	(113,805)		(61,806)		(51,999)		84.1	%	(22,170)		8,513		(30,683)		(360.4)	%
Consolidated net income	Consolidated net income		128,083		158,979				(30,896)		(19.4)	%	Consolidated net income	491,597		806,755		(315,158)		(39.1)	%	619,680		965,734		(346,054)		(35.8)	%
Net income attributable to non-controlling interests	Net income attributable to non-controlling interests		76,322		89,860				(13,538)		(15.1)	%	Net income attributable to non-controlling interests	187,093		365,979		(178,886)		(48.9)	%	263,415		455,839		(192,424)		(42.2)	%
Net income attributable to Royalty Pharma plc	Net income attributable to Royalty Pharma plc		$	51,761	$	69,119			$	(17,358)	(25.1)	%	Net income attributable to Royalty Pharma plc	$	304,504	$	440,776	$	(136,272)	(30.9)	%	$	356,265	$	509,895	$	(153,630)	(30.1)	%


(in thousands)	(in thousands)	For the Three Months Ended March 31,	2022 vs. 2021 Change				(in thousands)	For the Three Months Ended June 30,						Change				For the Six Months Ended June 30,				Change
			2022		2021				$		%			2022		2021		$		%		2022		2021		$		%
Cystic fibrosis franchise	Cystic fibrosis franchise		$	194,457	$	184,816			$	9,641	5.2	%	Cystic fibrosis franchise	$	201,664	$	185,597	$	16,067	8.7	%	$	396,121	$	370,413	$	25,708	6.9	%
Imbruvica	Imbruvica		87,627		99,115				(11,488)		(11.6)	%	Imbruvica	80,638		96,315		(15,677)		(16.3)	%	168,265		195,430		(27,165)		(13.9)	%
Tysabri	Tysabri		52,521		51,098				1,423		2.8	%	Tysabri	51,403		50,650		753		1.5	%	103,924		101,749		2,175		2.1	%
Xtandi	Xtandi		24,917		26,980				(2,063)		(7.6)	%	Xtandi	24,021		25,738		(1,717)		(6.7)	%	48,939		52,718		(3,779)		(7.2)	%
Promacta	Promacta		20,804		16,284				4,520		27.8	%	Promacta	23,786		19,680		4,106		20.9	%	44,590		35,964		8,626		24.0	%
Evrysdi			18,088		14,426				3,662		25.4	%
Tremfya													Tremfya	25,666		—		25,666		—	%	41,816		—		41,816		—	%
Other	Other		113,109		136,906				(23,797)		(17.4)	%	Other	108,172		125,434		(17,262)		(13.8)	%	223,218		276,765		(53,547)		(19.3)	%
Total income from financial royalty assets	Total income from financial royalty assets		$	511,523	$	529,625			$	(18,102)	(3.4)	%	Total income from financial royalty assets	$	515,350	$	503,414	$	11,936	2.4	%	$	1,026,873	$	1,033,039	$	(6,166)	(0.6)	%

Income from financial royalty assets increased by $11.9 million, or 2.4%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily driven by income related to newly acquired assets, primarily Tremfya, for which there was no comparable activity in the three months ended June 30, 2021, and the performance of the cystic fibrosis franchise. The increase was partially offset by the maturity of our royalties from the HIV franchise and declines in sell-side equity research analysts’ consensus sales forecasts for Imbruvica.

Income from financial royalty assets decreased by ~~$18.1~~$6.2 million, or ~~3.4%~~0.6%, in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the ~~three~~six months ended ~~March 31,~~June 30, 2021, primarily driven by the maturity of our royalties from the HIV franchise and declines in sell-side equity research analysts’ consensus sales forecasts for ~~Imbruvica and the maturity of our royalties from the HIV franchise.~~Imbruvica. The decrease in income was partially offset by income ~~related to~~from newly acquired assets, primarily Tremfya, ~~Cabometyx/Cometriq and Oxlumo,~~ for which there was no comparable activity in the ~~three~~six months ended ~~March 31, 2021.~~June 30, 2021, and the performance of the cystic fibrosis franchise and Promacta.


(in thousands)	(in thousands)	For the Three Months Ended March 31,					For the Three Months Ended March 31,		(in thousands)		For the Three Months Ended June 30, 2022						For the Three Months Ended June 30, 2021

Royalty	Royalty			2022		Royalty				2021			Royalty			For the Three Months Ended June 30, 2022			Royalty	For the Three Months Ended June 30, 2021
Imbruvica	Imbruvica	$	108,910		Imbruvica		$	63,414	Imbruvica				Tysabri
Tazverik		64,356			Cystic fibrosis franchise		53,092
IDHIFA		38,491			Tazverik		48,422
Cystic fibrosis franchise									Cystic fibrosis franchise			54,609			Xtandi			(101,172)
Promacta									Promacta		29,295			Cystic fibrosis franchise			(53,092)
Tysabri									Tysabri		(30,613)			Lexiscan			(34,286)
Xtandi	Xtandi	24,857			Xtandi		42,852		Xtandi		(43,804)			Imbruvica			46,378
Cystic fibrosis franchise		(48,636)			Emgality		35,236
Other	Other	46,224			Other		13,305		Other		38,220			Other			13,473
Total provision, exclusive of provision for credit losses	Total provision, exclusive of provision for credit losses	234,202			Total provision, exclusive of provision for credit losses		256,321		Total provision, exclusive of provision for credit losses		119,092			Total provision, exclusive of provision for credit losses			(243,053)
Provision for current expected credit losses	Provision for current expected credit losses	(49,581)			Provision for current expected credit losses		35,941		Provision for current expected credit losses		(13,378)			Provision for current expected credit losses			(709)
Total provision expense		$	184,621		Total provision expense		$	292,262
Total provision									Total provision		$	105,714		Total provision			$	(243,762)


(in thousands)	For the Six Months Ended June 30, 2022			For the Six Months Ended June 30, 2021
Product			Product
Imbruvica	$	180,294	Imbruvica	$	109,792
Tazverik	78,171		Tazverik	61,391
IDHIFA	38,112		Emgality	55,253
Promacta	29,295		Xtandi	(58,320)
Emgality	27,843		Tysabri	(112,720)
Other	(421)		Other	(42,129)
Total provision, exclusive of provision for credit losses	353,294		Total provision, exclusive of provision for credit losses	13,267
Provision for current expected credit losses	(62,959)		Provision for current expected credit losses	35,232
Total provision expense	$	290,335	Total provision	$	48,499

In the three months ended ~~March 31,~~June 30, 2022, we recorded provision expenseof ~~$184.6~~$105.7 million, comprised of ~~$234.2~~$119.1 million in provision expense for changes in expected cash flows and ~~$49.6~~$13.4 million in provision income for current expected credit losses. We recorded provision expense for changes in expected cash flows for Imbruvica and ~~Tazverik,~~the cystic fibrosis franchise primarily due to significant declines in sell-side equity research analysts’ consensus sales forecasts, which was partially offset by provision income for ~~the cystic fibrosis franchise~~Xtandi and Tysabri due to a significant increase in sell-side equity research analysts’ consensus sales forecasts. ~~During~~The provision income for credit losses was primarily driven by a decrease in current expected credit losses related to Tazverik as a result of the corresponding decline in the financial asset value.

In the three months ended ~~March 31,~~June 30, 2021, we recorded provision income of $243.8 million, of which $243.1 million and $0.7 million related to provision income for changes in expected cash flows and current expected credit losses, respectively. We recorded provision income primarily due to increases in sell-side equity research analysts’ consensus sales forecasts for Tysabri, Xtandi and the cystic fibrosis franchise. Offsetting the provision income was provision expense related to Imbruvica, primarily due to declines in sell-side equity research analysts’ consensus forecasts.

In the six months ended June 30, 2022, we recordedt provision expense heof $290.3 million, comprised of $353.3 million in provision expense for changes in expected cash flows and $63.0 million in provision income for current expected credit losses. We recorded provision expense for changes in expected cash flows for Imbruvica and Tazverik, primarily due to declines in sell-side equity research analysts’ consensus sales forecasts. The provision income for credit losses was primarily driven by a significant decrease in current expected credit losses related to Tazverik as a result of the corresponding significant decline in the financial asset value.

In the ~~three~~six months ended ~~March 31,~~June 30, 2021, we recorded provision expense of ~~$292.3~~$48.5 million, of which ~~$256.3~~$13.3 million and ~~$35.9~~$35.2 million related to provision expense for changes in expected cash flows and current expected credit losses, respectively. We recorded provision expense for Imbruvica, ~~the cystic fibrosis franchise, Tazverik, Xtandi and Emgality,~~ primarily due to declines in sell-side equity research analysts’ consensus sales ~~forecasts. During~~forecasts, and for Tazverik as a result of a slower than expected product launch. Offsetting the provision expense was provision income from a significant increase in ~~three~~sell-side equity research analysts’ consensus forecasts for Tysabri and Xtandi. During the six months ended ~~March 31,~~June 30, 2021, tthe he provision expense for current expected credit losses was primarily driven by ~~increases~~certain additions to our portfolio of financial royalty assets, including the incremental ~~$100~~$100.0 million financial royalty asset related to the start of the oral zavegepant Phase 3 program and a new royalty interest in Cabometyx/Cometriq.

Equity in earnings of equity method investees decreased by $14.6 million, or 92.8%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by a $21.5 million decrease in equity in earnings from the Legacy SLP Interest was $4.5 million and $5.2 million, in the three months ended March 31, 2022 and 2021, respectively. Equity in losses of the Avillion entities was $4.1 million and $7.1 million in the three months ended March 31, 2022 and 2021, respectively.Interest.

Other ~~expense,~~income, net ~~of $45.0~~increased by $78.5 million, or 96.3%, in the three months ended ~~March 31,~~June 30, 2022 ~~was~~compared to the three months ended June 30, 2021, primarily ~~comprised of losses on equity securities of $36.2 million~~ driven by ~~a net decrease in the share price~~gains on derivative instruments of ~~our investees~~$71.8 million and ~~losses~~higher gains on available for sale debt securities of $16.6 million, offset by interest income of $9.5 million primarily related to our Series A Biohaven Preferred Shares. The $16.6 million in unrealized losses on available for sales debt securities included a loss of $10.2 million related to the unrealized movement in fair value of the MorphoSys Development Funding Bond Forward for which there was no comparable activity in the prior period.

Other income, net increased by $64.5 million, or 127.6%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily ~~comprised~~driven by gains on derivative instruments of $71.8 million and higher gains on available for sale debt securities partially offset by losses on equity securities of ~~$54.2~~$28.1 million ~~driven a decreased share price of our investees. The decrease was partially offset by~~and lower interest income ~~of $16.6 million, primarily related to our Series A Biohaven Preferred Shares~~in the six months ended June 30, 2022. The gains on derivative instruments and ~~a gain of $9.1 million related to the unrealized movement in fair value of the Series B Biohaven Preferred Shares and related Series B Forwards recorded as~~ ~~Available~~higher gains on available for sale debt securities. are primarily driven by an estimated high probability of a change of control event for Biohaven within the next year.

Net income attributable to the Continuing Investors Partnerships decreased by ~~$17.9~~$93.7 million in the three months ended ~~March 31,~~June 30, 2022 as compared to the three months ended ~~March 31,~~June 30, 2021, primarily driven by lower net income attributable to RP Holdings in the three months ended ~~March 31,~~June 30, 2022. ~~The ongoing exchanges~~Exchanges by investors in the Continuing Investors Partnerships who indirectly own the RP Holdings Class B Interests for our Class A ordinary shares resulted in a decline in the Continuing Investors Partnerships’ ownership of RP Holdings.

Net income attributable to the Continuing Investors Partnerships decreased by $111.6 million in the six months ended June 30, 2022 as compared to the six months ended June 30, 2021, primarily driven by lower net income attributable to RP Holdings in the six months ended June 30, 2022. Exchanges by investors in the Continuing Investors Partnerships who indirectly own the RP Holdings Class B Interests for our Class A ordinary shares resulted in a decline in the Continuing Investors Partnerships’ ownership of RP Holdings.

•Tysabri. In April 2021, Biogen announced that the EC granted marketing authorization for a subcutaneous injection of Tysabri to treat relapsing-remitting multiple sclerosis. Biogen also announced that it had received a ~~Complete Response Letter~~complete response letter from the FDA for its ~~sBLA~~supplemental biologics license application for subcutaneous Tysabri. The ~~Complete Response Letter indicates~~complete response letter indicated that the FDA iswas unable to approve Biogen’s filing as submitted. ~~Biogen announced that it is evaluating the Complete Response Letter and will determine next steps in the United States.~~

•Imbruvica. In June 2021, ~~AbbVie~~Johnson and Johnson announced Phase 3 GLOW study results for Imbruvica in combination with Venetoclax for the treatment of first-line ~~CLL~~chronic lymphocytic leukemia and ~~SLL~~small lymphocytic lymphoma demonstrated superior progression-free survival versus chlorambucil plus obinutuzumab as a first-line treatment of ~~CLL.~~chronic lymphocytic leukemia. The study also showed improved duration of remission and significantly improved depth of remission. ~~AbbVie has~~Johnson & Johnson had indicated that approval could occur in 2022.

In August 2021, AbbVie announced that the U.S. District Court for the District of Delaware had issued a decision holding patent rights relating to Imbruvica were valid and infringed by a generic product from Alvogen and Natco. The decision, which is subject to appeal, prohibits regulatory approval of that generic product until the last AbbVie patent expires. Previously, AbbVie entered into several settlement and license agreements with other generic companies. Consequently, AbbVie does not expect any generic product entry prior to March 30, 2032, assuming pediatric exclusivity is granted.

In June 2022, Johnson & Johnson announced primary results from the Phase 3 SHINE study, which demonstrated that the combination of once-daily oral Imbruvica plus bendamustine-rituximab (BR) and rituximab maintenance significantly reduced the risk of disease progression or death by 25% compared to patients who received placebo plus BR and rituximab maintenance in patients aged 65 years or older with newly diagnosed mantle cell lymphoma. With a median follow-up of 84.7 months, the Imbruvica plus BR and rituximab maintenance combination showed a statistically significant and clinically meaningful 2.3 year improvement in median progression-free survival (6.7 years) vs. BR (4.4 years). The safety profile of the Imbruvica plus BR regimen was consistent with the known safety profiles of Imbruvica as well as BR.

In May 2022, Pfizer and Biohaven announced that they entered into a definitive agreement under which Pfizer will acquire Biohaven. Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash for a total of approximately $11.6 billion. Pfizer will also make payments at closing to settle Biohaven’s third-party debt and for the redemption of all outstanding shares of Biohaven’s redeemable preferred stock. The ~~EC approval will be valid for all 27 European Union member states as well as Iceland, Liechtenstein and Norway and local reimbursement approval will follow.~~transaction is expected to close by early 2023.

In November 2021, Gilead announced that the EC granted marketing authorization for Trodelvy as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease. The EC’s decision is supported by results from the Phase 3 ASCENT study where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with physician’s choice of chemotherapy.

In January 2022, Gilead announced it has entered into two clinical trial collaboration and supply agreements with Merck & Co. to evaluate the combination of Trodelvy and Merck & Co.’s anti-PD-1 therapy Keytruda in first-line metastatic non-small cell lung cancer (NSCLC). As part of the collaboration, Merck & Co. will sponsor a global Phase 3 clinical trial of Trodelvy in combination with Keytruda as a first-line treatment of patients with metastatic NSCLC.

In ~~March~~June 2022, Gilead announced results from the primary analysis of the Phase 3 TROPiCS-02 study ~~evaluating~~of Trodelvy versus physicians’ choice of chemotherapy in ~~patients with~~heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of ~~chemotherapy~~chemotherapy. The study met its primary endpoint of progression-free survival with a statistically significant ~~improvement in progression-free survival versus physician’s choice of chemotherapy. The trial targeted a 30%~~and clinically meaningful 34% reduction in the risk of disease progression or ~~death and the primary endpoint results were consistent with those observed in the Phase 1/2 IMMU-132-01 study in a subset of HR+/HER2- metastatic breast cancer patients.~~death. The first interim analysis of the key secondary endpoint of overall survival demonstrated a trend in ~~improvement for overall survival.~~improvement. Patients will be followed for a subsequent overall survival analysis. The safety profile for Trodelvy was consistent with prior studies.

•Cabometyx. In January 2021, Exelixis announced that the FDA approved Cabometyx for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in combination with Bristol Myers Squibb’s Opdivo. The approval was based on the Phase 3 CheckMate ~~-9ER~~9ER trial, in which the combination of Cabometyx and Opdivo significantly improved overall survival while doubling progression-free survival and objective response rate versus sunitinib as a first-line treatment for patients with advanced RCC.

In March 2021, Ipsen announced that the EC approved the combination of Cabometyx and Opdivo for the first-line treatment of advanced RCC.

In September 2021, Exelixis announced detailed results from the expanded Cohort 6 of the Phase 1b COSMIC-021 trial of Cabometyx in combination with atezolizumab in patients with metastatic ~~CRPC,~~castration-resistant prostate cancer, which included patients with metastatic ~~CRPC~~castration-resistant prostate cancer who had been previously treated with novel hormone therapies enzalutamide ~~and/~~or abiraterone acetate used along with prednisone. Following discussions with FDA, Exelixis announced that it will not pursue a regulatory submission for the combination regimen based on cohort 6 of COSMIC-021. Exelixis believes that CONTACT-02, a global Phase 3 pivotal trial that initiated enrollment in June 2020 may serve as a basis for future regulatory applications.

In March 2022, Exelixis announced results from the final analysis of the second primary endpoint of overall survival from the Phase 3 COSMIC-312 trial, which evaluated cabozantinib in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. The final analysis showed neither improvement nor detriment in overall survival for cabozantinib in combination with atezolizumab versus sorafenib.

In July 2022, Exelixis announced that COSMIC-313, an ongoing Phase 3 trial evaluating Cabometyx, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC, met its primary endpoint, demonstrating significant improvement in progression-free survival at the primary analysis. At a prespecified interim analysis for the secondary endpoint of overall survival, the combination of Cabometyx, nivolumab and ipilimumab did not demonstrate a significant benefit. The trial will continue to the next analysis of overall survival. Exelixis intends to discuss the results with the FDA to determine next steps toward a potential regulatory submission.

•Oxlumo. In July 2021, Alnylam announced results from ILLUMINATE-C, a Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 associated with progressive decline in renal function. Results from the primary analysis at six months demonstrated a substantial reduction in plasma oxalate from baseline in patients with advanced disease, including those on hemodialysis. The safety and tolerability profile of lumasiran following six months of treatment was encouraging across all ages, with no drug related serious adverse events and injection site reactions as the most common adverse event.

In March 2022, the FDA accepted Alnylam’s supplemental New Drug Application (“NDA”) for lumasiran for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1. The FDA has set an action date for October 6, 2022. Additionally, a Type II Variation for lumasiran to amend the label in patients with advanced ~~Primary Hyperoxaluria~~primary hyperoxaluria Type 1 was submitted and validated by the European Medicines Agency (“EMA”) in December 2021.

•Tremfya. In February 2022, Johnson & Johnson announced results from the Phase 2a VEGA proof-of-concept study. Results showed that the combination of Tremfya and golimumab, a tumor necrosis factor-alpha antagonist, induced higher rates of clinical response, clinical remission, endoscopic improvement and a composite histologic-endoscopic endpoint at 12 weeks than either treatment alone in adults with moderately to severely active ulcerative colitis. Rates of adverse events were comparable among treatment groups.

In February 2022, Johnson & Johnson announced results from the Phase 2b QUASAR Induction Study 1. Results showed that a significantly greater proportion of adults with moderately to severely active ulcerative colitis who previously had an inadequate response or intolerance to conventional therapies ~~and/~~or selected advanced therapies and were treated with Tremfya achieved clinical response at week 12 (Tremfya ~~200mg:~~200 mg: 61.4% and Tremfya ~~400mg:~~400 mg: 60.7%), the study’s primary endpoint compared with placebo (27.6%). Safety data at week 12 ~~were~~was consistent with the safety profile for Tremfya in approved indications.

~~ROYALTY PHARMA PLC~~

~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(UNAUDITED)~~

•Tazverik: In June 2022, Ipsen and Epizyme announced that they had entered into a definitive merger agreement under which Ipsen will acquire Epizyme. Ipsen intends to initiate a tender offer to acquire all outstanding shares of Epizyme at a price of $1.45 per share in cash at the closing of the transaction for an initial estimated aggregate consideration of $247 million plus a contingent value right of $1 per share. The transaction is anticipated to close by the end of the third quarter of 2022.

In February 2022, Cytokinetics announced positive topline results from Cohort 3 of the REDWOOD-HCM Phase 2 trial. Results from Cohort 3 showed that substantial reductions in the average resting left ventricular outflow tract pressure gradient (LVOT-G) as well as the post-Valsalva LVOT-G were achieved for patients with oHCM and a resting or post-Valsalva LVOT-G of ~~≥50~~greater than 50 mmHg whose background therapy included disopyramide and in the majority a beta-adrenergic blocker. The safety and tolerability of aficamten were consistent with prior experience in REDWOOD-HCM with no treatment interruptions and no serious adverse events attributed to treatment reported by the investigators.

•Gantenerumab. In October 2021, Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted ~~Breakthrough Therapy Designation~~breakthrough therapy designation by the FDA for the treatment of people living with Alzheimer’s disease. This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of Alzheimer’s disease, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies.

In March 2022, Roche announced a new Phase 3 Alzheimer’s disease prevention trial (SKYLINE). Roche has stated that it intends to enter into a collaboration agreement with Banner Alzheimer’s Institute’s Alzheimer’s Prevention Initiative, Massachusetts General Hospital and the University of Southern California Alzheimer’s Therapeutic Research Institute to further exchange scientific insights and advance the trial goals. SKYLINE aims to evaluate the potential of gantenerumab to slow disease progression in people with the earliest biologic signs of Alzheimer’s disease and who show no signs of cognitive impairment.

•Omecamtiv mecarbil. In February 2022, Cytokinetics announced that FDA has accepted and filed ~~the company’s New Drug Application (NDA)~~its NDA for omecamtiv mecarbil. The FDA assigned the NDA a standard review with a PDUFA ~~target action~~ date of November 30, 2022. The FDA also indicated that it is currently not planning to hold an advisory committee meeting to discuss the application. The submission is supported by GALACTIC-HF, which demonstrated a positive effect on the primary composite endpoint of cardiovascular death or heart failure events in patients with heart failure and reduced ejection fraction who were receiving standard of care plus omecamtiv mecarbil.

•Pelabresib. In December 2021, MorphoSys presented the latest data from the Phase 2 MANIFEST study evaluating pelabresib in the treatment of myelofibrosis. As of September 10, 2021, the data cut-off, a total of 84 JAK inhibitor-naive patients were enrolled and received the first-line combination of pelabresib and ruxolitinib. The data showed 68% (n=57) of patients treated with the combination achieved a greater than or equal to 35% reduction in spleen volume ~~(SVR35)~~ from baseline at week 24 and 60% (n=47) maintained ~~SVR35~~a greater than or equal to 35% reduction in spleen volume at week 48. Most patients also saw their symptoms reduced with 56% (n=46) achieving greater than or equal to 50% reduction in total symptom score from baseline at week 24.

•PT027. In September 2021, AstraZeneca and Avillion announced positive results from MANDALA and DENALI, two Phase 3 trials evaluating PT027 (albuterol/budesonide) in patients with asthma. PT027 is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. In MANDALA, PT027 demonstrated a statistically significant and clinically meaningful reduction in the risk of severe exacerbations compared to albuterol, when used as a rescue medicine in response to symptoms. In DENALI, PT027 showed a statistically significant improvement in lung function measured by forced expiratory volume in one second, compared to the individual components albuterol and budesonide, and compared to placebo. The safety and tolerability of PT027 in both trials was consistent with the known profiles of the components. ~~AstraZeneca has indicated PT027 regulatory submissions will occur in the first half of 2022.~~

In May 2022, Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, announced that FDA accepted for filing the NDA for AstraZeneca’s PT027. The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbation of asthma. The co-development partnership between AstraZeneca and Avillion also recently expanded to include the BATURA study, a randomized Phase 3b decentralized trial to further assess the role of PT027 in preventing asthma exacerbations.

In December 2021, Biohaven announced positive topline results from the second pivotal clinical trial evaluating the safety and efficacy of intranasal zavegepant for the acute treatment of migraine in adults. The Phase 3 study achieved its co-primary regulatory endpoints of pain freedom and freedom of most bothersome symptom at 2two hours and showed broad efficacy by demonstrating statistically significant superiority to placebo across a total of 15 prespecified primary and secondary outcome measures.

In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. There is no direct correlation between income from financial royalty assets and royalty receipts due to the nature of the accounting methodology applied for financial royalty assets. Further, income from financial royalty assets and the provision for changes in expected cash flows related to these financial royalty assets can be volatile and unpredictable. As a result, management places importance on royalty receipts as they are predictable and we use them as a measure of our operating performance. Refer to section titled “Non-GAAP Reconciliations” for additional discussion of management’s use of non-GAAP measures as supplemental financial measures and reconciliations from the most directly GAAP comparable measures of Net cash provided by operating activities.

Adjusted Cash Receipts is a measure calculated with inputs directly from the statements of cash flows and includes (1) royalty receipts by product: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) Other royalty cash collections, (iii) Distributions from equity method investees, plus (2) Proceeds from available for sale debt securities; less (1) Distributions to non-controlling interests, which ~~represents~~represent contractual distributions of royalty receipts and proceeds from available for sale debt securities to our historical non-controlling interests related to the Legacy Investors Partnerships and RPSFT. Adjusted Cash Receipts is most directly comparable to the GAAP measure of Net cash provided by operating activities.

Adjusted EBITDA and Adjusted Cash Flow are similar non-GAAP liquidity measures that are both most closely comparable to the GAAP measure, Net cash provided by operating activities. Adjusted EBITDA is important to our lenders and is defined under the Credit Agreement as Adjusted Cash Receipts less Payments for operating and professional costs. Payments for operating and professional costs are comprised of Payments for operating and professional costs and Payments for rebates from the statements of cash flows.

Adjusted Cash Flow is defined as Adjusted EBITDA less (1) Development-stage funding payments - ongoing, (2) D~~evelopment-stage~~Development-stage funding payments - upfront and ~~milestones~~milestone, (3) Interest paid, net of Interest received, (4) Investments in equity method investees and (5) Other (including Derivative collateral posted, net of Derivative collateral received, and Termination payments on derivative instruments) plus (1) Contributions from non-controlling interests- R&D, all directly reconcilable to the statements of cash flows.

Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, as derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants.


Royalties	Royalties	For the Three Months Ended March 31,			2022 vs. 2021 Change				Royalties		For the Three Months Ended June 30,							For the Six Months Ended June 30,								Six Months Year-to-Date Change
			2022		2021		$			%		Royalties		2022				2021				2022				2021				$				%

Cystic fibrosis franchise (1)	Cystic fibrosis franchise (1)		$	201,882	$	166,809	$	35,073		21.0	%		Cystic fibrosis franchise (1)			$	181,968			$	156,023			$	383,851			$	322,832			$	61,019		18.9	%
Tysabri	Tysabri		97,439		86,921		10,518			12.1	%	Tysabri		93,128				92,070				190,567				178,991				11,576				6.5	%
Imbruvica	Imbruvica		87,171		89,135		(1,964)			(2.2)	%	Imbruvica		80,381				87,289				167,552				176,424				(8,872)				(5.0)	%
Xtandi												Xtandi		51,988				35,767				95,383				76,812				18,571				24.2	%
Promacta	Promacta		47,897		44,126		3,771			8.5	%	Promacta		34,715				32,341				82,612				76,466				6,146				8.0	%
Xtandi			43,395		41,045		2,350			5.7	%
Januvia, Janumet, Other DPP-IVs (2)	Januvia, Janumet, Other DPP-IVs (2)		35,682		35,761		(79)			(0.2)	%	Januvia, Janumet, Other DPP-IVs (2)		35,695				39,438				71,377				75,200				(3,823)				(5.1)	%

Tremfya	Tremfya		28,224		—		28,224			—	%	Tremfya		18,428				—				46,653				—				46,653				—	%
Nurtec ODT/Biohaven payment (3)	Nurtec ODT/Biohaven payment (3)		20,375		16,501		3,874			23.5	%	Nurtec ODT/Biohaven payment (3)		18,715				16,721				39,090				33,222				5,868				17.7	%
Cabometyx/Cometriq	Cabometyx/Cometriq		12,857		—		12,857			—	%	Cabometyx/Cometriq		13,055				10,129				25,911				10,129				15,782				155.8	%
Farxiga/Onglyza	Farxiga/Onglyza		9,469		8,562		907			10.6	%	Farxiga/Onglyza		11,346				9,113				20,815				17,675				3,140				17.8	%
Evrysdi	Evrysdi		9,197		1,677		7,520			*		Evrysdi		8,134				2,971				17,331				4,648				12,683				272.9	%
Prevymis												Prevymis		9,997				8,772				14,123				17,402				(3,279)				(18.8)	%
Trodelvy	Trodelvy		4,892		2,605		2,287			87.8	%	Trodelvy		6,040				2,992				10,932				5,597				5,335				95.3	%
Erleada	Erleada		4,886		3,104		1,782			57.4	%	Erleada		4,834				3,116				9,720				6,220				3,500				56.3	%
Emgality			4,764		3,264		1,500			46.0	%
Crysvita	Crysvita		4,712		3,588		1,124			31.3	%	Crysvita		4,933				3,929				9,645				7,516				2,129				28.3	%
Orladeyo	Orladeyo		4,426		12		4,414			*		Orladeyo		4,765				957				9,191				969				8,222				*
Prevymis			4,126		8,630		(4,504)			(52.2)	%
Emgality												Emgality		4,425				3,550				9,188				6,814				2,374				34.8	%

Oxlumo	Oxlumo		766		—		766			—	%	Oxlumo		583				—				1,349				—				1,349				—	%
Other products (4)	Other products (4)		88,871		137,738		(48,867)			(35.5)	%	Other products (4)		50,038				82,502				138,909				220,241				(81,332)				(36.9)	%
Total royalty receipts	Total royalty receipts		$	711,031	$	649,478	$	61,553		9.5	%	Total royalty receipts		$	633,168			$	587,680			$	1,344,199			$	1,237,158			$	107,041			8.7	%
Distributions to non-controlling interests	Distributions to non-controlling interests		(106,385)		(125,721)		19,336			(15.4)	%	Distributions to non-controlling interests		(109,158)				(112,476)				(215,543)				(238,197)				22,654				(9.5)	%
Adjusted Cash Receipts (non-GAAP)	Adjusted Cash Receipts (non-GAAP)		$	604,646	$	523,757	$	80,889		15.4	%	Adjusted Cash Receipts (non-GAAP)		$	524,010			$	475,204			$	1,128,656			$	998,961			$	129,695			13.0	%
Payments for operating and professional costs	Payments for operating and professional costs		(48,902)		(42,160)		(6,742)			16.0	%	Payments for operating and professional costs		(44,101)				(39,604)				(93,003)				(81,764)				(11,239)				13.7	%
Adjusted EBITDA (non-GAAP)	Adjusted EBITDA (non-GAAP)		$	555,744	$	481,597	$	74,147		15.4	%	Adjusted EBITDA (non-GAAP)		$	479,909			$	435,600			$	1,035,653			$	917,197			$	118,456			12.9	%
Development-stage funding payments - ongoing	Development-stage funding payments - ongoing		(500)		(2,641)		2,141			(81.1)	%	Development-stage funding payments - ongoing		(606)				(3,122)				(1,106)				(5,763)				4,657				(80.8)	%
Development-stage funding payments - upfront and milestones			(100,000)		—		(100,000)			—	%
Interest paid, net			(85,734)		(62,952)		(22,782)			36.2	%
Development-stage funding payments - upfront and milestone												Development-stage funding payments - upfront and milestone		—				—				(100,000)				—				(100,000)				—	%
Interest received/(paid), net												Interest received/(paid), net		2,116				784				(83,618)				(62,168)				(21,450)				34.5	%
Investments in equity method investees	Investments in equity method investees		(3,050)		(8,714)		5,664			(65.0)	%	Investments in equity method investees		—				(8,713)				(3,050)				(17,427)				14,377				(82.5)	%

Contributions from non-controlling interests- R&D	Contributions from non-controlling interests- R&D		624		1,997		(1,373)			(68.8)	%	Contributions from non-controlling interests- R&D		107				2,083				731				4,080				(3,349)				(82.1)	%
Other												Other		—				2,130				—				2,130				(2,130)				(100.0)	%
Adjusted Cash Flow (non-GAAP)	Adjusted Cash Flow (non-GAAP)		$	367,084	$	409,287	$	(42,203)		(10.3)	%	Adjusted Cash Flow (non-GAAP)		$	481,526			$	428,762			$	848,610			$	838,049			$	10,561			1.3	%

Weighted average Class A ordinary shares outstanding - diluted	Weighted average Class A ordinary shares outstanding - diluted		607,201		607,148							Weighted average Class A ordinary shares outstanding - diluted		607,214				607,163				607,207				607,151

Adjusted Cash Receipts increased by ~~$80.9~~$129.7 million to ~~$604.6 million~~$1.1 billion in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the ~~three~~six months ended ~~March 31,~~June 30, 2021, primarily driven by an increase ~~of $72.6 million~~ in royalty receipts from ~~existing products, including~~ the cystic fibrosis franchise and newly acquired royalties, which was partially offset by a decline ~~of $52.9 million~~in royalty receipts from matured royalties, primarily the HIV ~~franchise. Additionally, we received royalty receipts of $41.8 million in the three months ended March 31, 2022 from newly acquired assets, primarily Tremfya, Cabometyx/Cometriq~~franchise, and ~~Oxlumo,~~unfavorable foreign exchange movements. The increase in Adjusted Cash Receipts also reflects a decline in distributions to non-controlling interests due to maturing royalties jointly owned by the ~~legacy investors.~~Legacy Investors Partnerships and RPSFT.

•Cystic fibrosis franchise – Royalty receipts from the cystic fibrosis franchise, which includes Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio, which are marketed by Vertex for patients with certain mutations causing cystic fibrosis, increased by ~~$35.1~~$61.0 million in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the ~~three~~six months ended ~~March 31,~~June 30, 2021. The increase was primarily driven by the launch of Kaftrio in ~~multiple~~ additional countries outside the United States and the performance of Trikafta in the United States, including its uptake in children 6 through 11 years old.

•Imbruvica – Royalty receipts from Imbruvica, which is marketed by AbbVie and Johnson & Johnson for the treatment of blood cancers and chronic graft versus host disease, decreased by ~~$2.0~~$8.9 million in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the ~~three~~six months ended ~~March 31, 2021, primarily driven by~~June 30, 2021. The decrease was largely due to a slower-than-anticipated ~~market~~ recovery ~~from COVID-19 in~~of the chronic lymphocytic leukemia market from COVID-19 and increased ~~share pressure~~competition from newer therapies in the United States. ~~This decline was partially offset~~

•Promacta – Royalty receipts from Promacta, which is marketed by Novartis for the treatment of chronic immune thrombocytopenia purpura (ITP) and aplastic anemia, increased by ~~$3.8~~$6.1 million in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the ~~three~~six months ended ~~March 31,~~June 30, 2021. This growth was primarily driven by increased use in ITP and further uptake as first-line treatment for severe aplastic anemia in the United States.

•Nurtec ODT/Biohaven payment – Royalty receipts from Nurtec ODT, marketed by Biohaven and Pfizer for the acute and preventative treatment of migraine, increased by ~~$3.9~~$5.9 million in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the ~~three~~six months ended ~~March 31, 2021.~~June 30, 2021, primarily driven by prescription volume growth. In addition, we received ~~$15.6~~$31.3 million in fixed payments from Biohaven related to the Series A Biohaven Preferred Shares during each of the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021.

Distributions to non-controlling interests decreased by ~~$19.3~~$22.7 million to ~~$106.4~~$215.5 million in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the ~~three~~six months ended ~~March 31,~~June 30, 2021, which positively impacted Adjusted Cash Receipts. The decrease in distributions to non-controlling interests is primarily due to maturing royalties jointly owned by the ~~legacy investors.~~Legacy Investors Partnerships and RPSFT.

Adjusted EBITDA increased by ~~$74.1~~$118.5 million to ~~$555.7 million~~$1.0 billion in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the ~~three~~six months ended ~~March 31,~~June 30, 2021 as a result of the factors noted above in “Adjusted Cash Receipts (Non-GAAP).”. Payments for operating and professional costs, the only adjustment between Adjusted Cash Receipts and Adjusted EBITDA, increased in ~~three~~the six months ended ~~March 31,~~June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by higher Operating and Personnel Payments ~~due to~~from increased cash receipts from royalty investments.

Adjusted Cash Flow ~~decreased~~increased by ~~$42.2~~$10.6 million to ~~$367.1~~$848.6 million in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the ~~three~~six months ended ~~March 31,~~June 30, 2021, primarily driven by the factors noted above in “Adjusted Cash Receipts (non-GAAP)” and “Adjusted EBITDA (non-GAAP).” The increase was partially offset by upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product candidate and a ~~$22.8~~$21.5 million increase in net interest paid in the ~~three~~six months ended ~~March 31,~~June 30, 2022 due to the first interest payment on the 2021 Notes. The decrease in Adjusted Cash Flow was partially offset by the increases in “Adjusted Cash Receipts” and “Adjusted EBITDA” (non-GAAP) noted above and lower funding requirements by the Avillion Entities.

Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are non-GAAP measures presented as supplemental measures to our GAAP financial performance. These non-GAAP financial measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because our operating performance is a function of our liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. We caution readers that amounts presented in accordance with our definitions of Adjusted Cash Receipts, Adjusted EBITDA, and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures we use in the same manner. We compensate for these limitations by using non-GAAP financial measures as supplements to GAAP financial measures and by presenting the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures, in each case being Net cash provided by operating activities.

We believe that Adjusted Cash Receipts and Adjusted Cash Flow provide meaningful information about our operating performance because the business is heavily reliant on its ability to generate consistent cash flows and these measures reflect the core cash collections and cash charges comprising our operating results. Management strongly believes that our significant operating cash flow is one of the attributes that attracts potential investors to our business.

In addition, we believe that Adjusted Cash Receipts and Adjusted Cash Flow help identify underlying trends in the business and permit investors to more fully understand how management assesses ~~the~~our performance, ~~of the Company,~~ including planning and forecasting for future periods. Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of ~~the Company’s~~our ability to generate cash from operations. Both measures are an indication of ~~the~~our strength ~~of the Company~~ and the performance of the business. Management uses Adjusted Cash Receipts and Adjusted Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, voluntary debt repayments, dividends and other discretionary investments. Further, these non-GAAP financial measures help management, the audit committee and investors evaluate our ability to generate liquidity from operating activities.

Management believes that Adjusted EBITDA is an important non-GAAP measure in analyzing our liquidity and is a key component of certain material covenants contained within ~~the Company’s~~our credit agreement. Noncompliance with the interest coverage ratio and leverage ratio covenants under the credit agreement could result in our lenders requiring ~~the Company~~us to immediately repay all amounts borrowed. If we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of our liquidity.

Management uses Adjusted Cash Flow to evaluate its ability to generate cash and performance of the business and to evaluate ~~the Company’s~~our performance as compared to its peer group. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income measures used by many companies in the biopharmaceutical industry, even though each company may customize its own calculation and therefore one company’s metric may not be directly comparable to another’s. We believe that non-GAAP financial measures, including Adjusted Cash Flow, are frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry.

To arrive at Adjusted Cash Receipts, we start with the GAAP line item, Net cash provided by operating activities, and adjust for the following items from the statements of cash flows: to add back (1) Proceeds from available for sale debt securities (redemption of Biohaven Preferred Shares), which are cash inflows that management believes are derived from royalties and form part of our core business strategy, (2) Distributions from equity method investees which are classified as cash inflows from investing activities, (3) Interest paid, net of Interest received, (4) Development-stage funding payments, (5) Payments for operating and professional costs, (6) Payments for rebates and (7) Termination payments on derivative instruments, and to deduct (1) Distributions to non-controlling interests, which represents distributions to our historical non-controlling interests related to the Legacy Investors Partnerships and RPSFT, and (2) Derivative collateral posted or (received), net, both of which are excluded when management assesses its operating performance through cash collections, or Adjusted Cash Receipts.

To arrive at Adjusted EBITDA, we start with Net cash provided by operating activities and adjust for the following items from the statements of cash flows: to add back (1) Proceeds from available for sale debt securities (redemption of Biohaven Preferred Shares), (2) Distributions from equity method investees which are classified as cash inflows from investing activities, (3) Interest paid, net of Interest received, (4) Development-stage funding payments and (5) Termination payments on derivative instruments, and to deduct (1) Distributions to non-controlling interests and (2) Derivative collateral posted or (received), net.

To arrive at Adjusted Cash Flow, we start with Net cash provided by operating activities and adjust for the following items from the statements of cash flows: to add back (1) Proceeds from available for sale debt securities (redemption of Biohaven Preferred Shares), (2) Distributions from equity method investees classified as cash inflows from investing activities and (3) Contributions from non-controlling interests-R&D, and to deduct (1) Distributions to non-controlling interests and (2) Investments in equity method investees. This is intended to present an Adjusted Cash Flow measure that is representative of cash generated from the broader business strategy of acquiring royalty-generating assets that are available for reinvestment and for discretionary purposes.


(in thousands)	(in thousands)	For the Three Months Ended March 31,			(in thousands)	For the Three Months Ended June 30,						For the Six Months Ended June 30,
			2022				2021			2022		2021		2022		2021
Net cash provided by operating activities (GAAP)	Net cash provided by operating activities (GAAP)		$	460,270			$	526,100	Net cash provided by operating activities (GAAP)	$	574,952	$	531,720	$	1,035,222	$	1,057,820
Adjustments:	Adjustments:								Adjustments:
Proceeds from available for sale debt securities (1), (2)	Proceeds from available for sale debt securities (1), (2)		15,625				15,625		Proceeds from available for sale debt securities (1), (2)	15,625		15,625		31,250		31,250

Interest paid, net (2)			85,734				62,952
Distributions from equity method investees – investing (2)									Distributions from equity method investees – investing (2)	—		523		—		523
Interest (received)/paid, net (2)									Interest (received)/paid, net (2)	(2,116)		(784)		83,618		62,168
Development-stage funding payments - ongoing (3)	Development-stage funding payments - ongoing (3)		500				2,641		Development-stage funding payments - ongoing (3)	606		3,122		1,106		5,763
Development-stage funding payments - upfront and milestones (3)			100,000				—
Development-stage funding payments - upfront and milestone (3)									Development-stage funding payments - upfront and milestone (3)	—		—		100,000		—
Payments for operating and professional costs	Payments for operating and professional costs		48,902				42,160		Payments for operating and professional costs	44,101		39,604		93,003		81,764

Distributions to non-controlling interests (2)	Distributions to non-controlling interests (2)		(106,385)				(125,721)		Distributions to non-controlling interests (2)	(109,158)		(112,476)		(215,543)		(238,197)

Derivative collateral received, net (2)									Derivative collateral received, net (2)	—		(2,130)		—		(2,130)
Adjusted Cash Receipts (non-GAAP)	Adjusted Cash Receipts (non-GAAP)		$	604,646			$	523,757	Adjusted Cash Receipts (non-GAAP)	$	524,010	$	475,204	$	1,128,656	$	998,961

Net cash provided by operating activities (GAAP)	Net cash provided by operating activities (GAAP)		$	460,270			$	526,100	Net cash provided by operating activities (GAAP)	$	574,952	$	531,720	$	1,035,222	$	1,057,820
Adjustments:	Adjustments:								Adjustments:
Proceeds from available for sale debt securities (1), (2)	Proceeds from available for sale debt securities (1), (2)		15,625				15,625		Proceeds from available for sale debt securities (1), (2)	15,625		15,625		31,250		31,250

Interest paid, net (2)			85,734				62,952
Distributions from equity method investees – investing (2)									Distributions from equity method investees – investing (2)	—		523		—		523
Interest (received)/paid, net (2)									Interest (received)/paid, net (2)	(2,116)		(784)		83,618		62,168
Development-stage funding payments - ongoing (3)	Development-stage funding payments - ongoing (3)		500				2,641		Development-stage funding payments - ongoing (3)	606		3,122		1,106		5,763
Development-stage funding payments - upfront and milestones (3)			100,000				—
Development-stage funding payments - upfront and milestone (3)									Development-stage funding payments - upfront and milestone (3)	—		—		100,000		—

Distributions to non-controlling interests (2)	Distributions to non-controlling interests (2)		(106,385)				(125,721)		Distributions to non-controlling interests (2)	(109,158)		(112,476)		(215,543)		(238,197)

Derivative collateral received, net (2)									Derivative collateral received, net (2)	—		(2,130)		—		(2,130)
Adjusted EBITDA (non-GAAP)	Adjusted EBITDA (non-GAAP)		$	555,744			$	481,597	Adjusted EBITDA (non-GAAP)	$	479,909	$	435,600	$	1,035,653	$	917,197

Net cash provided by operating activities (GAAP)	Net cash provided by operating activities (GAAP)		$	460,270			$	526,100	Net cash provided by operating activities (GAAP)	$	574,952	$	531,720	$	1,035,222	$	1,057,820
Adjustments:	Adjustments:								Adjustments:
Proceeds from available for sale debt securities (1), (2)	Proceeds from available for sale debt securities (1), (2)		15,625				15,625		Proceeds from available for sale debt securities (1), (2)	15,625		15,625		31,250		31,250

Distributions from equity method investees – investing (2)									Distributions from equity method investees – investing (2)	—		523		—		523

Contributions from non-controlling interests-R&D (2)	Contributions from non-controlling interests-R&D (2)		624				1,997		Contributions from non-controlling interests-R&D (2)	107		2,083		731		4,080
Distributions to non-controlling interests (2)	Distributions to non-controlling interests (2)		(106,385)				(125,721)		Distributions to non-controlling interests (2)	(109,158)		(112,476)		(215,543)		(238,197)
Investments in equity method investees (2), (4)	Investments in equity method investees (2), (4)		(3,050)				(8,714)		Investments in equity method investees (2), (4)	—		(8,713)		(3,050)		(17,427)
Adjusted Cash Flow (non-GAAP)	Adjusted Cash Flow (non-GAAP)		$	367,084			$	409,287	Adjusted Cash Flow (non-GAAP)	$	481,526	$	428,762	$	848,610	$	838,049


~~(1) Receipts from the quarterly redemption of the Series A Biohaven Preferred Shares are presented as~~ ~~Proceeds from available for sale debt securities~~ ~~on the statements of cash flows.~~
~~(2) The table below shows the line item for each adjustment and the direct location for such line item on the statements of cash flows.~~

Reconciling Adjustment	Statements of Cash Flows Classification
Proceeds from available for sale debt securities	Investing activities
Investments in equity method investees	Investing activities
Distributions to non-controlling interests	Financing activities
Interest (received)/paid, net	Operating activities (Interest paid less Interest received)
Derivative collateral received, net	Operating activities (Derivative collateral received less Derivative collateral posted)
Contributions from non-controlling interests- R&D	Financing activities


(3) Our lenders consider all payments made to support R&D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. All ongoing and upfront development-stage funding payments are reported in R&D funding expense in net income and are added back in aggregate to ~~Net cash provided by operating activities~~ ~~to arrive at Adjusted EBITDA. As a result, Adjusted EBITDA captures the full add-back for development-stage funding payments.~~
(4) We consider all payments to fund our operating joint ventures that are performing R&D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by ourDistributions from equity method investees ~~the Avillion Entities, are deducted to arrive at Adjusted Cash Flow, but are not deducted in Adjusted EBITDA.~~- investing		Investing activities

(3)Our lenders consider all payments made to support R&D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. All ongoing development-stage funding payments and upfront and milestone development-stage funding payments are reported in R&D funding expense in net income and are added back in aggregate to Net cash provided by operating activities to arrive at Adjusted EBITDA. As a result, Adjusted EBITDA captures the full add-back for development-stage funding payments.

(4)We consider all payments to fund our operating joint ventures that are performing R&D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by our equity method investees, the Avillion Entities, are deducted to arrive at Adjusted Cash Flow, but are not deducted in Adjusted EBITDA.

Ongoing investment in new royalties is fundamental to the long-term prospects of our business. New investments provide a source of growth for our royalty receipts, supplementing growth within our existing portfolio and offsetting declines for royalties on products that have lost market exclusivity. We evaluate an array of royalty acquisition opportunities on a continuous basis and expect to continue to make acquisitions in the ordinary course of our business. ~~Our team has~~We have established a strong track record of identifying, evaluating and investing in royalties tied to leading products across therapeutic areas and treatment modalities. We invest in approved products and development-stage product candidates that have generated robust proof of concept data. We invest in these therapies through the purchase of royalties, by making hybrid investments and by acquiring businesses with significant existing royalty assets or the potential for the creation of such assets.

For the ~~three~~six months ended ~~March 31,~~June 30, 2022, we invested ~~$202.2~~$442.4 million in royalties and related assets. While volatility exists in the ~~quantum~~total amount of our new acquisitions on a year-to-year basis due to the unpredictable timing of new investment opportunities, we have consistently deployed significant amounts of cash when measured over multi-year periods. Our approach is rooted in a highly disciplined evaluation process that is not dictated by a minimum annual investment threshold.

•In July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance Biopharma, Inc. (“Theravance”) and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy for an upfront payment of $1.31 billion and up to $300 million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25 million in upfront funding and a potential $15 million regulatory milestone payment to support the clinical development of ampreloxetine.

•In January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (“Cytokinetics”) for $150 million comprised of an upfront payment of $50 million and two additional $50 million payments, conditional upon the initiation of potential pivotal clinical trials for oHCM and nonobstructive hypertrophic cardiomyopathy, respectively. In February 2022, Cytokinetics announced that it initiated the clinical trial for oHCM, which triggered a $50 million payment from us in March 2022. Additionally, we will provide Cytokinetics long-term capital of up to $300 million (“Cytokinetics Commercial Launch Funding”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50 million funded upon closing. Cytokinetics is required to draw $25 million if a certain contingency is met and has the option to draw the remaining $225 million upon the occurrence of certain regulatory and clinical development milestones.

•In November 2021, we acquired incremental royalty interests in BCX9930 and Orladeyo (berotralstat) from BioCryst for an upfront cash payment of $150 million. Additionally, we paid $50 million to purchase 3,846 thousand shares of BioCryst common stock, ~~in BioCryst,~~ which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. The funds from this transaction will enable further advancement of BCX9930 and support additional investment in the global launch of Orladeyo (berotralstat).

•In June 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support ~~MorphoSys’~~its acquisition of Constellation Pharmaceuticals, Inc. (“Constellation”), which closed on July 15, 2021. We agreed to provide up to $2.025 billion of funding to MorphoSys, comprised of an upfront payment of $1.425 billion, additional milestone payments of up to $150 million, up to $350 million of capital (“Development Funding Bonds”)~~, which~~. Following an amendment in June 2022, MorphoSys may draw ~~over a one-year period from~~ the ~~close of its acquisition of Constellation.~~funding by September 12, 2022. MorphoSys is required to draw a minimum of $150 million of Development Funding Bonds. In connection with the closing of ~~MorphoSys’~~its acquisition of Constellation, we purchased 1,337,552 ordinary shares of MorphoSys for $100 million at a price of €63.35 per ordinary share, based on the average trading price of the ordinary shares over a period preceding the closing of the acquisition.

•In January 2021, we acquired a royalty interest in seltorexant from Minerva Neurosciences, Inc. for an upfront payment of $60 million and up to $95 million in additional milestone payments, contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder ~~(MDD)~~ with insomnia symptoms by Johnson & Johnson.

Additionally, in April 2021, we entered into an agreement with MSCI, ~~Inc. (“MSCI”),~~ a leading provider of critical decision support tools and services, to assist MSCI in the design of a classification framework and index methodologies to expand MSCI’s thematic index suite with the launch of new indexes. In return, we will receive a portion of MSCI’s revenues from those indexes. The financial impact associated with this transaction has not been material to date and is not expected to be material for the year ended December 31, 2022.

Our primary source of liquidity is cash provided by operations. For both the ~~three~~six months ended ~~March 31,~~June 30, 2022 and 2021, we generated ~~$460.3 million~~$1.0 billion and ~~$526.1 million,~~$1.1 billion, respectively, in Net cash provided by operating activities. We believe that our existing capital resources, cash provided by operating activities and our Revolving Credit Facility (defined below) will continue to allow us to meet our operating and working capital requirements, to fund planned strategic acquisitions and R&D funding arrangements, and to meet our debt service obligations for the foreseeable future. We have historically operated at a low level of fixed operating costs. Our primary cash operating expenses, other than R&D funding commitments, include interest expense, our Operating and Personnel Payments, and legal and professional fees.

We have access to substantial sources of funds in the capital markets and we may, from time to time, seek additional capital through a combination of additional debt or equity financings. In July 2021, we issued $1.3 billion of senior unsecured notes. Additionally, we have a Revolving Credit Facility (defined below) which provides for borrowing capacity of up to $1.5 billion that remains undrawn and available to us as of ~~March 31,~~June 30, 2022. As of ~~March 31,~~June 30, 2022 and December 31, 2021, we had total long-term debt outstanding of $7.1 billion and $7.1 billion, respectively.

We have historically funded our acquisition program through free cash flow, equity contributions and debt. Our low operating costs coupled with a lack of capital expenditures and low taxes have contributed to our strong financial profile, resulting in high operating leverage and high conversion of our Adjusted Cash Receipts to Adjusted Cash Flow. We expect to continue funding our current and planned operating costs (excluding acquisitions) principally through our cash flow from operations and our acquisition program through cash flow and issuances of equity and debt. In the past, we have supplemented our available cash and cash equivalents on hand with attractive debt capital to fund certain strategic acquisitions.


(in thousands)	(in thousands)	For the Three Months Ended March 31,				2022 vs. 2021		(in thousands)	For the Six Months Ended June 30,				2022 vs. 2021
		2022		2021		Change			2022		2021		Change
Cash provided by (used in):	Cash provided by (used in):							Cash provided by (used in):
Operating activities	Operating activities	$	460,270	$	526,100	$	(65,830)	Operating activities	$	1,035,222	$	1,057,820	$	(22,598)
Investing activities	Investing activities	11,165		(599,300)		610,465		Investing activities	(19,013)		(473,134)		454,121
Financing activities	Financing activities	(220,966)		(226,670)		5,704		Financing activities	(449,220)		(451,085)		1,865

Cash provided by operating activities decreased by ~~$65.8~~$22.6 million in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the ~~three~~six months ended ~~March 31,~~June 30, 2021, primarily driven by upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product ~~candidate.~~candidate in the six months ended June 30, 2022. Additionally, interest paid increased by ~~$21.7~~$22.4 million in the ~~three~~six months ended ~~March 31,~~June 30, 2022 due to the first interest payment made on the 2021 Notes. The higher use of cash was partially offset by an increase in cash collections from financial royalty assets of ~~$47.7~~$87.3 million.

Cash ~~provided by investing activities was $11.2 million in the three months ended March 31, 2022 compared to cash~~ used in investing activities ~~of $599.3~~decreased by $454.1 million in the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by a ~~$503.0~~$508.6 million decrease in cash used to acquire financial royalty assets and a ~~$182.8~~$150.4 million increase in the overall net cash provided by marketable securities. Additionally, ~~in the three months ended March 31, 2022,~~ we paid approximately ~~$84.0~~$62.8 million to ~~purchase available for sales debt securities related to Cytokinetics Commercial Launch Funding and additional~~acquire equity securities ~~in Epizyme.~~during the six months ended June 30, 2022 compared to the receipt of proceeds of $109.4 million from the sale of all of our Cytokinetics common stock and a portion of our Biohaven common shares during the six months ended June 30, 2021.

As of ~~March 31,~~June 30, 2022, our cash and cash equivalents and marketable securities totaled ~~$1.8~~$2.1 billion and ~~$484.2~~$290.4 million, respectively. As of December 31, 2021, our cash and cash equivalents and marketable securities totaled $1.5 billion and $581.9 million, respectively. We intend to fund short-term and long-term financial obligations as they mature through cash and cash equivalents, sales of marketable securities, future cash flows from operations or the issuance of additional debt. Our ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the sales of the underlying pharmaceutical products in which we hold royalties, deterioration in our key financial ratios or credit ratings, or other material unfavorable changes in business conditions. Currently, we believe that we have sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support our growth objectives.

Date of Issuance Maturity March 31, 2022 December 31, 2021
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par) 9/2020 9/2023 $ 1,000,000 $ 1,000,000
$1,000,000, 1.20% (issued at 98.875% of par) 9/2020 9/2025 1,000,000 1,000,000
$1,000,000, 1.75% (issued at 98.284% of par) 9/2020 9/2027 1,000,000 1,000,000
$1,000,000, 2.20% (issued at 97.760% of par) 9/2020 9/2030 1,000,000 1,000,000
$600,000, 2.15% (issued at 98.263% of par) 7/2021 9/2031 600,000 600,000
$1,000,000, 3.30% (issued at 95.556% of par) 9/2020 9/2040 1,000,000 1,000,000
$1,000,000, 3.55% (issued at 95.306% of par) 9/2020 9/2050 1,000,000 1,000,000
$700,000, 3.35% (issued at 97.565% of par) 7/2021 9/2051 700,000 700,000
Total senior unsecured debt 7,300,000 7,300,000
Unamortized debt discount and issuance costs (198,862) (203,930)
Total long-term debt $ 7,101,138 $ 7,096,070

~~ROYALTY PHARMA PLC~~

~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(UNAUDITED)~~


	Date of Issuance	Maturity	As of June 30, 2022		As of December 31, 2021
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)	9/2020	9/2023	$	1,000,000	$	1,000,000
$1,000,000, 1.20% (issued at 98.875% of par)	9/2020	9/2025	1,000,000		1,000,000
$1,000,000, 1.75% (issued at 98.284% of par)	9/2020	9/2027	1,000,000		1,000,000
$1,000,000, 2.20% (issued at 97.760% of par)	9/2020	9/2030	1,000,000		1,000,000
$600,000, 2.15% (issued at 98.263% of par)	7/2021	9/2031	600,000		600,000
$1,000,000, 3.30% (issued at 95.556% of par)	9/2020	9/2040	1,000,000		1,000,000
$1,000,000, 3.55% (issued at 95.306% of par)	9/2020	9/2050	1,000,000		1,000,000
$700,000, 3.35% (issued at 97.565% of par)	7/2021	9/2051	700,000		700,000
Total senior unsecured debt			7,300,000		7,300,000
Unamortized debt discount and issuance costs			(193,801)		(203,930)
Total long-term debt			$	7,106,199	$	7,096,070

On July 26, 2021, we issued the 2021 Notes with a weighted average coupon rate of 2.80% and requiring annual interest payments of approximately $36.4 million, paid semi-annually. On September 2, 2020, we issued $6.0 billion of senior unsecured note (the “2020 Notes”) with a weighted average coupon rate of 2.125% and requiring annual interest payments of approximately $127.5 million, paid semi-annually. We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. We refer to the 2020 Notes and 2021 Notes, collectively, as the ~~“Notes”.~~“Notes.” Indentures governing the Notes contain certain covenants with which we were in compliance as of ~~March 31,~~June 30, 2022.

On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”). The Credit Agreement amends and restates the credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured Revolving Credit Facility with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. The Credit Agreement contains certain customary covenants which we were in compliance as of ~~March 31,~~June 30, 2022. The Revolving Credit Facility remains undrawn and available to us as of ~~March 31,~~June 30, 2022.

•~~Synthetic/Hybrid Royalties~~Synthetic Royalties/R&D Funding – Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone ~~payments, or be structured as a long-term stream of fixed-payments with a predetermined schedule. In many of our synthetic royalties, we~~payments. We also ~~make investments in the public equity of the company, where the main value driver of the company is the product for which we concurrently acquired a royalty.~~

•M&ARelated – We acquire royalties in connection with M&A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.

In January 2022, we entered into a long-term funding agreement with Cytokinetics to provide capital up to $300 million of capital (“Cytokinetics Commercial Launch Funding”) available in five tranches to support Cytokinetics for further development of aficamten and potential commercialization of omecamtiv mecarbil. We funded the initial tranche of $50 million of the Cytokinetics Commercial Launch Funding upon ~~closing.~~closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw ~~$25~~$50 million if a certain contingency is met and has the option to draw the remaining ~~$225~~$200 million upon the occurrence of certain regulatory and clinical development milestones. As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022.

In June 2021, we announced a long-term strategic funding partnership with MorphoSys to support ~~MorphoSys’~~its acquisition of Constellation, which closed on July 15, 2021. As part of the ~~partnership,~~funding agreement, which was amended in the three months ended June 30, 2022 to extend the required draw date, we agreed to provide MorphoSys up to $350 million of Development Funding Bonds ~~which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation.~~to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $150 ~~million of Development Funding Bonds.~~million. In return, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. As of ~~March 31,~~June 30, 2022, MorphoSys has not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $300 million under the Development Funding Bonds to be funded in September 2022.

We may have other funding arrangements where we are contractually obligated to fund R&D activities performed by our development ~~partners and to provide additional capital~~partners. We also have funding arrangements related to our equity method investment in the Avillion ~~entities.~~Entities. As our committed capital requirements are based on phases of development, the completion of which is highly uncertain, only the capital required to fund the current stage of development under such funding arrangements is considered committed capital requirements, which approximate ~~$36.7~~$52.7 million as of ~~March 31,~~June 30, 2022.

We also have certain milestone payments that are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. As such, these contingent milestone payments are not considered contractual obligations. In the ~~three~~six months ended ~~March 31,~~June 30, 2022, we made a $50 million payment to Cytokinetics in connection with ~~their~~its initiation of the first pivotal clinical trial in oHCM. In the ~~three~~six months ended ~~March 31,~~June 30, 2021, we made a $100 million payment to Biohaven related to a development milestone that was achieved upon the start of the oral zavegepant Phase 3 program.

Under the Management Agreement, we pay quarterly Operating and Personnel Payments equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of our security investments under GAAP as of the end of each quarter. Because the Operating and Personnel Payments are determined based on cash receipts, the amounts are variable. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&A expenses on an ongoing basis.

Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary (the “Guarantor Subsidiary”). Our remaining subsidiaries (the “Non-Guarantor Subsidiaries”) do not guarantee the Notes. Under the terms of the indenture governing the Notes, Royalty Pharma plc and the Guarantor Subsidiary each fully and unconditionally, jointly and severally, guarantee the payment of interest, principal and premium, if any, on the Notes. As of ~~March 31,~~June 30, 2022, the par value and carrying value of the total outstanding and guaranteed Notes was $7.3 billion and $7.1 billion, respectively.

The following financial information presents summarized combined balance sheet information as of ~~March 31,~~June 30, 2022 and December 31, 2021 and summarized combined ~~statements~~statement of operations information for the ~~three~~six months ended ~~March 31,~~June 30, 2022 for Royalty Pharma plc and RP Holdings. All intercompany balances and transactions between Royalty Pharma plc and RP Holdings are eliminated in the presentation of the combined financial statements. RP Holdings’ most significant asset is its investment in operating subsidiaries, which has been eliminated in the table below to exclude investments in Non-Guarantor Subsidiaries. Our operating subsidiaries hold the majority of our cash and cash equivalents, marketable securities and financial royalty assets. As a result, our ability to make required payments on the Notes depends on the performance of our operating subsidiaries and their ability to distribute funds to us. There are no material restrictions on distributions from the operating subsidiaries. Amounts presented below do not represent our total consolidated amounts as of ~~March 31,~~June 30, 2022 and December 31, 2021 or for the ~~three~~six months ended ~~March 31,~~June 30, 2022.

Summarized Combined Balance Sheet As of As of
(in thousands) March 31, 2022 December 31, 2021
Current assets $ 45,001 $ 95,946
Current interest receivable on intercompany notes due from Non-Guarantor Subsidiaries 4,889 16,974
Non-current assets 3,870 4,145
Non-current intercompany notes receivable due from Non-Guarantor Subsidiaries 2,058,336 2,039,576
Current liabilities 15,369 59,030
Current interest payable on intercompany notes due to Non-Guarantor Subsidiaries 3,766 16,974
Non-current liabilities 7,100,476 7,095,450
Non-current intercompany notes payable due to Non-Guarantor Subsidiaries 2,013,336 2,039,576


Summarized Combined Balance Sheet
(in thousands)	As of June 30, 2022		As of December 31, 2021
Current assets	$	57,188	$	95,946
Current interest receivable on intercompany notes due from Non-Guarantor Subsidiaries	17,725		16,974
Non-current assets	3,591		4,145
Non-current intercompany notes receivable due from Non-Guarantor Subsidiaries	2,038,611		2,039,576

Current liabilities	56,646		59,030
Current interest payable on intercompany notes due to Non-Guarantor Subsidiaries	15,370		16,974

Non-current liabilities	7,105,495		7,095,450
Non-current intercompany notes payable due to Non-Guarantor Subsidiaries	1,993,611		2,039,576

The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Certain of these policies are considered critical as they have the most significant impact on our financial condition and results of operations and require the most difficult, subjective, or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain. On an ongoing basis, we evaluate our estimates that are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of income and expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Our most critical accounting policies relate to our financial royalty assets. Similarly, the most significant judgments and estimates applied by management are associated with the measurement of our financial royalty assets at amortized cost using the prospective effective interest method. The application of the prospective approach to calculate interest income from our financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. There have been no material changes to our critical accounting policies and estimates as described in our Annual Report on Form 10-K.

We are subject to certain risks which may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates and interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the nature of the marketable securities we hold. In order to manage our exposures, we follow established risk management policies and procedures, including the use of derivative financial instruments, such as swaps, rate locks and forwards. We do not enter into derivative instruments for trading or speculative purposes. The counterparties to these contracts are all major financial institutions.

Our results of operations are subject to foreign currency exchange risk through transactional exposure resulting from movements in exchange rates between the time we recognize royalty income or royalty revenue and the time at which the transaction settles, or we receive the royalty payment. The current portion of ~~Financial royalty assets, net~~ ~~and~~ ~~Accrued royalty receivable~~ account for the most common types of transactional exposure. Because we are entitled to royalties on worldwide sales for various products, there is an underlying exposure to foreign currency as the marketer converts payment amounts from local currencies to U.S. dollars using a quarterly average exchange rate. Therefore, cash received may differ from the estimated receivable based on fluctuations in currency. In addition, certain products pay royalties in currencies other than U.S. dollars, which also creates foreign currency risk primarily with respect to the Euro, Canadian Dollar, Swiss Franc and Japanese Yen, as our functional and reporting currency is the U.S. dollar. To manage foreign currency exchange risk, we may periodically utilize non-deliverable forward exchange contracts. We do not currently have any foreign exchange contracts in place.

We are subject to interest rate fluctuation exposure through our investments in money market accounts and marketable securities, the majority of which bear a variable interest rate. As of March 31, 2022, we held cash and cash equivalents of $1.8 billion, of which $1.3 billion was cash, $84.1 million was invested in commercial paper and U.S. government securities and $421.3 million was invested in interest-bearing money market funds. We also held $484.2 million in marketable securities as of March 31, 2022 invested in certificates of deposit, commercial paper and U.S. government securities.

The objectives of our investment policy are the preservation of capital and fulfillment of liquidity needs. In order to maximize income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds and marketable securities, largely composed of investment grade, short to intermediate term fixed income and debt securities. Because of the short term maturities of our cash equivalents and the short term nature of our marketable securities, we do not believe that a decrease in interest rates would have any material negative impact on the fair value of our cash equivalents or marketable securities.

Our debt portfolio is managed on a consolidated basis and management makes financing decisions to achieve the lowest cost of debt capital and to maximize portfolio objectives. As of March 31, 2022, 100% of our outstanding debt has fixed interest rates. We have a $1.5 billion Revolving Credit Facility with a variable interest rate that remained undrawn as of March 31, 2022. We are subject to interest rate fluctuation exposure related to the Revolving Credit Facility, if drawn.

We are exposed to credit risk related to the counterparties with which we do business. We are subject to credit risk from our royalty assets, our receivables and our derivative financial instruments. The majority of our royalty assets and receivables arise from contractual royalty agreements that pay royalties on the sales of underlying pharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading biopharmaceutical industry participants, including, among others, AbbVie, Gilead, Johnson & Johnson, Merck & Co., Pfizer, Astellas, Novartis, Biogen and Vertex. As of March 31, 2022 and December 31, 2021, Vertex, as marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% of our current portion of ~~Financial royalty assets, net, and represented the largest individual marketer and payor of our royalties.~~

We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements and to our derivative financial instruments so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets or on the settlement of our derivative financial instruments. If a counterparty becomes bankrupt, or otherwise fails to perform its obligations under a derivative financial instruments due to financial difficulties, we may experience significant delays in obtaining any recovery under the derivative financial instruments in a bankruptcy or other reorganization proceeding.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were, in design and operation, effective to the reasonable assurance level.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.

~~From time~~For a description of our legal proceedings, refer to ~~time, we or the Manager may be a party to various claims, charges~~Note 14–Commitments and litigation matters arising in the ordinary course of business. Management and legal counsel regularly review the probable outcome of such proceedings. While we cannot feasibly predict the outcome of these matters with certainty, we believe, based on examination of these matters, experience to date and discussions with counsel, that the ultimate liability, individually or in the aggregate, will not adversely affect our business, financial condition or results of operations.Contingencies, which is incorporated herein by reference.


England and Wales									98-1535773
(State or other jurisdiction of incorporation or organization)									(I.R.S. Employer Identification No.)

110 East 59th Street
New York, New York 10022


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Class A ordinary shares, par value $0.0001	RPRX	The Nasdaq Stock Market LLC


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐


(in thousands)	Principal Payments		Interest Payments
Year
Remainder of 2022	$	—	$	81,925
2023	1,000,000		163,850
2024	—		156,350
2025	1,000,000		156,350
2026	—		144,350
Thereafter	5,300,000		2,070,250
Total (1)	$	7,300,000	$	2,773,075


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


	Three Months Ended March 31, 2022								Three Months Ended March 31, 2021
	Equity Securities		Debt Securities		Forwards		Funding Commitments			Equity Securities		Debt Securities		Forwards		Funding Commitments
Balance at the beginning of the period	$	43,013	$	253,700	$	16,700	$	—		$	—	$	214,400	$	18,600	$	—
Purchases	—		64,579		—		—			—		17,585		—		—
Gains/(losses) on initial recognition (1)	—		9,400		—		(9,400)			—		—		—		—
Gains on equity securities	19,525		—		—		—			—		—		—		—
Unrealized gains included in other comprehensive losses (2)	—		1,625				—			—		5,125		—		—
Unrealized (losses)/gains included in earnings (3)	—		(1,600)		(15,979)		1,000			—		—		9,115		—
Settlement of forwards (4)	—		1,921		(1,921)		—			—		5,315		(5,315)		—
Redemption of debt securities	—		(15,625)		—		—			—		(15,625)		—		—
Balance at the end of the period	$	62,538	$	314,000	$	(1,200)	$	(8,400)		$	—	$	226,800	$	22,400	$	—


Summarized Combined Balance Sheet	As of		As of
(in thousands)	March 31, 2022		December 31, 2021
Current assets	$	45,001	$	95,946
Current interest receivable on intercompany notes due from Non-Guarantor Subsidiaries	4,889		16,974
Non-current assets	3,870		4,145
Non-current intercompany notes receivable due from Non-Guarantor Subsidiaries	2,058,336		2,039,576

Current liabilities	15,369		59,030
Current interest payable on intercompany notes due to Non-Guarantor Subsidiaries	3,766		16,974

Non-current liabilities	7,100,476		7,095,450
Non-current intercompany notes payable due to Non-Guarantor Subsidiaries	2,013,336		2,039,576


Summarized Combined Statement of Operations	For the ~~Three~~Six Months Ended ~~March 31,~~ June 30, 2022
(in thousands)

Interest income on intercompany notes receivable from Non-Guarantor Subsidiaries	$	~~14,139~~28,181
Other income	56
Operating expenses	~~52,254~~104,266
Interest expense on intercompany notes payable with Non-Guarantor Subsidiaries	~~13,016~~25,826

Net loss	~~51,131~~101,855


Exhibit No.			Description of Exhibit
31.1*			Certification of the Registrant ’s Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934
31.2*			Certification of the Registrant ’s Chief Financial Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934
32*			Certification of the Registrant’ Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS			XBRL Instance Document
101.SCH			XBRL Schema Document
101.CAL			XBRL Calculation Linkbase Document
101.DEF			XBRL Definition Linkbase Document
101.LAB			XBRL Label Linkbase Document
101.PRE			XBRL Presentation Linkbase


ROYALTY PHARMA PLC
(Registrant)

~~Date: May 5, 2022~~						/s/ Pablo Legorreta
						Pablo Legorreta
						Chief Executive Officer

Date: ~~May 5,~~August 4, 2022

/s/ Terrance Coyne
						Terrance Coyne
						Chief Financial Officer

Date: August 4, 2022